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Amal Y. Al‑Yasiri5,6, Darsha K. D. MohanDoss7, Michael B. Nicholl8, Ademar B. Lugão4,
Chetan P. Hans9 & Kattesh V. Katti1,10,11*
Men with castration-resistant prostate cancer (CRPC) face poor prognosis and increased
risk of treatment-incurred adverse effects resulting in one of the highest mortalities among
patient population globally. Immune cells act as double-edged sword depending on the tumor
microenvironment, which leads to increased infiltration of pro-tumor (M2) macrophages.
Development of new immunomodulatory therapeutic agents capable of targeting the tumor
microenvironment, and hence orchestrating the transformation of pro-tumor M2 macrophages to
anti-tumor M1, would substantially improve treatment outcomes of CRPC patients. We report, herein,
Mangiferin functionalized gold nanoparticulate agent (MGF-AuNPs) and its immunomodulatory
characteristics in treating prostate cancer. We provide evidence of immunomodulatory intervention of
MGF-AuNPs in prostate cancers through observations of enhanced levels of anti-tumor cytokines (IL12 and TNF-α) with concomitant reductions in the levels of pro-tumor cytokines (IL-10 and IL-6). In the
MGF-AuNPs treated groups, IL-12 was elevated to ten-fold while TNF-α was elevated to about 50-fold,
while IL-10 and IL-6 were reduced by two-fold. Ability of MGF-AuNPs to target splenic macrophages
is invoked via targeting of NF-kB signaling pathway. Finally, therapeutic efficacy of MGF-AuNPs, in
treating prostate cancer in vivo in tumor bearing mice, is described taking into consideration various
immunomodulatory interventions triggered by this green nanotechnology-based nanomedicine
agent.
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CBC	Complete blood count
CPZ	Chlorpromazine
CRPC	Castration-resistant prostate cancer
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DAPI	4′,6-Diamidino-2-phenylindole
DCFH-DA	2,7-Dichlorofluorescin diacetate
DPBS	Dulbecco’s phosphate buffered saline
DLS	Dynamic Light Scattering
DU-145	Androgen receptor positive human prostate cancer cells
EDS	Energy-dispersive X-ray spectroscopy
EGCG	Epigallocatechin gallate
EGFR	Epidermal growth factor
EMT	Epithelial-mesenchymal transition
FACS	Fluorescence-Activated Cell Sorting
FGFR	Fibroblast growth factor
Fn-3	Anti-fibronectin AB
FITC	Fluorescein isothiocyanate
HSA	Human serum albumin
HAECs	Human aortic endothelial cells
IAEA	United Nation’s International Atomic Energy Agency
ICP-MS	Inductively Coupled Plasma Mass Spectrometry
IKK	IκB kinase
IκBs	NF-κB proteins
LNCaP	Lymph node carcinoma of the prostate cell line
M1	Anti-tumor macrophages
M2	Pro-tumor macrophages
MDSCs	Myeloid-derived suppressor cells
MGF	Mangiferin
MGF-AuNPs	Mangiferin functionalized gold nanoparticles
MMP	Matrix metalloproteinase
MLuC5	Laminin receptor antibody
MPS	Mononuclear phagocyte system
MVD	Micro-vessel density
MURR	University of Missouri Research reactor
NAA	Neutron Activation Analysis
NF-kB	Nuclear factor kappa-light-chain-enhancer of activated B cells
NK	Natural killer
LPS	Lipopolysaccharide
PBS	Phosphate buffered saline
PC-3	Human prostate tumor cells
PCR	Polymerase chain reaction
PDGFR	Platelet derived growth factor
PFA	Paraformaldehyde
PI	Propidium iodide
PXRD	Powder X ray diffraction
RAW 264.7	Murine macrophage cells
RPMI	Roswell Park Memorial Institute
S-AuNPs	Starch-stabilized gold nanoparticles
SCID	Severely combine immune-deficient
SCNC	Small Cell Neuroendocrine Carcinoma
SPR	Surface plasmon resonance
TAMs	Tumor associated macrophages
TEM	Transmission Electron Microscopy
TNF-α	Tumor necrosis factor alpha
VEGFR	Vascular endothelial growth factor
X-22	Anti-clathrin AB
The latest epidemiological investigation (spanning January 1, 2008–March 31, 2018) of patients with castrationresistant prostate cancer (mCRPC) has concluded high mortality suggesting a significant unmet clinical need
in prolonging life span of human population inflicted with this deadly disease g lobally1–4. There is an emerging consensus that current therapies are poorly effective for patients with castration-resistant prostate cancer
(CRPC), where the disease manifests from asymptomatic or minimally symptomatic, non-metastatic disease to
symptomatic or highly metastatic condition, depending on the time of diagnosis with significant interpatient
variation5–7. The United States Food and Drug Administration (FDA) has approved several chemotherapeutic
agents including docetaxel, cabazitaxel, abiraterone, and enzalutamide for treating such patients. Drug resistance,
attributable to modulation of myeloid-derived suppressor cells (MDSCs), is seen in a significant proportion of
CRPC patients. Myeloid-derived suppressor cells (MDSCs) induce an immune suppressive microenvironment
and promote the M2-polarized tumor associated macrophages (TAMs). These macrophages present remarkable
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ability to suppress T-cell responses thus supporting angiogenesis and metastasis of CRPC. Macrophages, the
myeloid derived immune cells of the innate immune system, manifest two states of polarization (M1 and M2)
that develop in direct response to different stimuli. The polarization and differentiation of macrophages into
the cancer-inhibiting M1 and cancer-promoting M2 phenotypes represent the two states of macrophages in the
tumor microenvironment8–10.
Numerous studies have also shown that tissue and serum exosomes from prostate cancer patients induced
higher levels of macrophage polarization into an alternatively activated M2 (pro-tumor) p
 henotype11–13. The
interaction of polarized macrophages with cancer cells plays a crucial role in a variety of cancers including
prostate cancers9,14,15. Several investigations have provided important insights on the role of the polarization of
macrophages from M1 into M2 phenotypes and how this macrophage axis is directly involved in prostate cancer
initiation, progression, and m
 etastasis16–18. An additional contributing factor for enhanced levels of pro-tumor
M2 phenotypes in a vast majority of prostate and most solid tumors is attributed to elevated NF-κB signaling,
upregulated by the release of cytokines by M2 macrophages, in the tumor m
 icroenvironment19,20. Compelling
evidence shows that chemotherapeutic and radiation treatments of solid cancers in general, and prostate tumors
in particular, activates NF-κB, a key transcription factor that plays a critical role in the development and progression of cancers and consequently aiding chemo and multi therapy drug resistance. Upregulated NF-κB activity
can activate pro-survival pathways, including BCL-2. Therefore, cancer treatment emphasizing personalized
therapy through immune boosting precision medicine, capable of targeting M2 macrophages, is distinguished
from a plethora of “common denominator” treatment approaches in current use21–23.
In the context of developing novel therapies for treating drug-resistant cancers such as castration-resistant
prostate cancer (CRPC), high antioxidant capacity and immunomodulatory phytochemicals are gaining considerable scientific and clinical interests24,25. Anti-neoplastic activity of phytochemicals mainly depends on their multitarget mechanism of action, including their ability to modulate the host immune response to cancer, reducing
inflammatory microenvironment and enhancing lymphocyte o
 ncosurveillance26–28. Numerous therapeutic effects
of various phytochemicals are believed to be based on mechanisms of modulation of innate immunity more
specifically macrophage f unction29,30. Since carcinogenesis is multi-factorial activity involving several signaling
pathways, multi targeted phytochemicals therefore represent a promising therapeutic domain in o
 ncology31,32.
However, one of the major challenges, which continue to impede the application of phytochemicals, in cancer
treatment is associated with achieving adequate bioavailability at tolerable doses. This is a vexing problem in
translating promising findings from cell culture and animal models into clinically efficacious phytochemicalbased drugs.
Nanotechnology offers practical and scientifically most effective means to create multitudes of signatures of
phytochemicals on individual nanoparticles—thus enhancing bioavailability to achieve optimum therapeutic
payloads at the tumor site33–35. Over the last two decades, we have successfully demonstrated that large surface
area of gold nanoparticles can be embedded with a plethora of phytochemicals to create biocompatible cancer
therapeutic nanomedicine agents33–51. Our extensive results, using tumor bearing rodents as well as in tumor
bearing dogs (where the disease mimics spontaneously occurring tumors in human patients), have demonstrated
optimum therapeutic efficacy using tolerable doses33–51. Our investigations, therefore, provide compelling rationale to develop phytochemical-embedded immunomodulatory nanomedicine agents for use in a wide array of
applications in o
 ncology33–51.
In view of the extraordinary importance of immunomodulatory intervention in treating mCRPC, we focused
our attention on the creation of Mangiferin encapsulated gold nanoparticles (MGF-AuNPs). Mangiferin, used
extensively in ancient medicine, is a glucose-functionalized xanthonoid found in large abundance in mangoes
fruit peel52. Several studies have shown that Mangiferin exerts antioxidant activities, inhibitory effects on type II
5α-reductase in vitro, gastroprotective and also antidiabetic effects in rodents53–57. Administration of Mangiferin
in swiss mice have shown in vivo growth-inhibitory activity against ascitic fibrosarcoma58. This phytochemical
has demonstrated enhanced tumor cell cytotoxicity of the splenic cells and peritoneal macrophages of normal
and tumor-bearing mice59. Mechanistic investigations have revealed that Mangiferin causes decreased matrix
metalloproteinase (MMP)-7 and -9 activities with concomitant reversal of epithelial-mesenchymal transition
(EMT)60. There is conclusive evidence that the mechanism of modulation of MMP-7 and -9, and EMT is due to
the innate ability of Mangiferin to inhibit β-catenin p
 athway61,62. Enzymatic degradation, in vivo, has impeded
the clinical applications of this important immunomodulatory phytochemical in oncology.
Our hypothesis was that encapsulation of Mangiferin (MGF) on gold nanoparticles would create a new
nanomedicine agent, MGF-AuNP, enabling improved cellular uptake of MGF-AuNPs for exerting effective
immunomodulatory intervention via targeting the tumor microenvironment. In the present article, we give a
conceptual overview on how a new generation of immunotherapeutic agent derived through green nanotechnology, integrating Mangiferin phytochemical onto well-defined gold nanoparticles (MGF-AuNPs), can be developed for use in prostate cancer therapy. Interestingly, combination of gold metal with phytochemicals has been
used for over 5000 years in the Indian holistic Ayurvedic Medicine63–71. Our green nanotechnology approach
of encapsulating Mangiferin onto gold nanoparticles represents an integrative momentum to merge the best of
two worlds of modern nanomedicine with the traditional Ayurvedic medicine.
We describe, herein, experimental evidence that Mangiferin functionalized gold nanoparticulate nanomedicine agent, (MGF-AuNPs), successfully manipulates the M1 and M2 polarization axis through two main
approaches for applications in prostate cancer therapy: (1) specific interference with M2-like tumor associated
macrophages (TAM) survival or inhibiting their signaling cascades and (2) repolarization of tumor-promoting
M2-like TAMs to a tumoricidal M1-like phenotype. We also describe evidence of immunomodulatory intervention of MGF-AuNPs in prostate cancers through observations of enhanced levels of anti-tumor cytokines,
such as IL-12 and TNF-α, with concomitant reductions in the levels of pro-tumor cytokines, such as IL-10 and
IL-6. Additionally, we provide concrete details on cellular interrogation to establish that MGF-AuNPs target
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Scheme 1.  Green Nanotechnology Architecture of Mangiferin functionalized Gold Nanoparticles (MGFAuNPs).

laminin receptors, over expressed on prostate tumor cells, thus presenting a compelling case for applications
of this nanomedicine agent in the treatment of laminin receptor-positive human tumors for both diagnosis
and therapy. Ability of MGF-AuNPs to target splenic macrophages is invoked via targeting of NF-κB signaling
pathway; and thus, resulting in reeducation/polarization of macrophages from pro-tumor M2 to anti-tumor M1
macrophages. Finally, therapeutic efficacy of MGF-AuNPs, in treating prostate cancer in vivo in tumor bearing
mice, is described taking into consideration various immunomodulatory interventions triggered by this green
nanotechnology-based nanomedicine agent. Full mechanistic details of immunotherapeutic effects of MGFAuNPs and how tumor microenvironment targeting ability of this nanomedicine agent will play a crucial role
in prostate tumor therapy are described.

Results and discussion

Green nanotechnological architecture of MGF‑AuNPs. Mangiferin (1,3,6,7-tetrahydroxyxanthoneC2-D glucoside) is a polyphenol comprising of D-glucoside functionalized with a xanthone (Scheme 1)72. This
phytochemical is found in abundance in the Anacardiaceae and Gentianaceae family of plant species especially
in mango skin and honeybush t ea73. Following our pioneering efforts of using Phytochemicals of plants to produce tumor specific gold n
 anoparticles33–51, we have utilized a highly innovative green nanotechnology process
to functionalize Mangiferin onto gold nanoparticles to produce Mangiferin encapsulated gold nanoparticles:
MGF-AuNPs (Scheme 1). Antioxidant phytochemicals can act as electron reservoirs to transform metals into
their corresponding nanoparticles. The high antioxidant capacity of Mangiferin, as reflected through its oxidation potential (Epa = 0.32 V), offered a unique opportunity to use this phytochemical to transform gold salt into
the corresponding nanoparticles (AuNPs). We have now optimized a highly reproducible and a scalable process
wherein interaction of appropriate amounts of Mangiferin with gold salt produced the corresponding phytochemical-encapsulated gold nanoparticles (MGF-AuNPs) in aqueous media (Scheme 1). The excess Mangiferin
from the reaction mixture creates a robust encapsulation around gold nanoparticles thus eliminating the need
for external chemical agents for stabilization against agglomeration of MGF-AuNPs. The green nanotechnology
process, as depicted in Scheme 1, offers a great example of a ‘zero carbon footprint’ process because, other than
the gold salt, no other human-derived toxic chemicals were used in the overall production of MGF-AuNPs.
Full characterization details of MGF-AuNPs using combinations of techniques including UV–visible Spectrophotometry, Dynamic Light Scattering (DLS), Transmission Electron Microscopy (TEM), Inductively Coupled
Plasma Mass Spectrometry (ICP-MS), Energy-Dispersive X-ray Spectroscopy (EDS) and Powder X ray Diffraction (PXRD)—are all outlined in the supplementary materials section (Figures S1–S4).
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Figure 1.  Receptor mediated endocytosis of MGF-AuNPs. (A,D): Untreated PC-3 cells; (B,E): MGF-AuNPs
(41 µM) treated PC-3 cells; (C,F): Laminin receptors on PC-3 cells blocked with ABLR antibody and post
treated with MGF-AuNPs, results from images B and E showing laminin receptor affinity of MGF-AuNPs in
PC-3 cells. Optical images by dark field microscopy (CytoViva) and microscopic images by TEM techniques.

Prostate tumor cell specificity and receptor mediated endocytosis of MGF‑AuNPs. We rationalized the choice PC-3 cells in our investigations based on ample evidence that suggests that PC-3 and DU-145
are androgen receptor deficient cells and that they do not respond to hormone therapy. One of the ways of treating patients with androgen receptor deficient conditions is through castration. However, this strategy does not
improve the survival outcome significantly. Between PC-3 and DU-145, PC-3 tumors are more aggressive and
metastatic. Androgen therapy resistant prostate tumors are more aggressive, metastatic, and fatal. Considering all these facts, we chose PC-3 cell line to develop xenograft tumors in severely combine immune-deficient
(SCID) mice (see subsequent sections on therapeutic efficacy to address treatment inefficiency of current treatment strategies for androgen (castration)-resistant prostate cancers). We did not use androgen therapy sensitive
prostate cancer cell line as we focused our efforts on CRPCs.
Previous studies from our laboratories have shown that polyphenolic structural motif of epigallocatechin
gallate (EGCG) exhibit selective binding affinities (in the sub nanomolar ranges) with laminin receptors which
are overexpressed in prostate and various other tumor c ells33,41. We reasoned that the chemical structure of
Mangiferin, which comprises of a glucose moiety (Scheme 1), should allow significantly efficient accumulation
of MGF-AuNPs within tumor cells due to the Warburg e ffect74,75. We hypothesized that the Warburg effects,
in conjunction with laminin receptor specificity of Mangiferin, are expected to provide selective and enhanced
tumor accumulation of MGF-AuNPs in tumor cells. In order to establish laminin receptor specificity and high
binding affinity of MGF-AuNPs toward laminin receptors, we have performed detailed mechanistic investigations
on the endocytosis pathways of MGF-AuNPs in prostate tumor cells as discussed below.
It is well-known that prostate tumor cells overexpress laminin receptors (67 kDa LR)76. Laminin receptor is an
important protein involved in cell adhesion to the basement membrane as well as in the signaling transduction
following this binding e vent77. In our experiments, we have probed the specificity of MGF-AuNPs toward laminin
receptors that are over expressed in prostate tumor cells derived from human prostate tumors (PC-3 cells) (Fig. 1,
Scheme 2). Briefly, PC-3 cells were treated with MGF-AuNPs, in two separate experiments involving the presence and absence of laminin receptor antibody ( MLuC5), in our efforts to discern the laminin receptor mediated
endocytosis of MGF-AuNPs. When the laminin receptors were not blocked by MLuC5 antibody, we observed very
efficient endocytosis of MGF-AuNPs into PC-3 cells as shown in Fig. 1B (Dark field microscopy) and E (Transmission electron microscopy). We then saturated the laminin receptors on PC-3 cells using MLuC5 antibody
and subsequently allowed these cells to interact with MGF-AuNPs. Microscopic analysis of these cells clearly
revealed inhibition of MGF-AuNPs to internalize into PC-3 cells as shown in Fig. 1C (Dark field microscopy)
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Scheme 2.  Mechanisms of endocytosis, cellular entry and cellular trafficking pathways of MGF-AuNPs into
prostate tumor cells.
and F (Transmission electron microscopy). We rationalize our findings on the basis that pre-incubation of PC-3
cells with MLuC5 antibody saturates Lam 67 receptors on prostate cancer cells and thus reduces or eliminates the
ability of MGF-AuNPs to bind to laminin receptors on these cells. The above results, of pre- and post-blocking,
of laminin receptors by M
 LuC5 antibody—taken together—unequivocally reveal that Mangiferin corona, on
MGF-AuNPs, serves as a powerful laminin receptor targeting agent. These results, therefore, provide compelling
evidence that MGF-AuNPs have the potential for use as tumor specific gold nanoparticles in molecular imaging
and therapy of various laminin receptor-positive tumors.
In order to further establish tumor cell specificity of MGF-AuNPs, we have performed laminin receptor blocking experiments using a non-specific antibody, anti-fibronectin AB (Fn-3), and mouse IgG Isotype as a control.
Our selection of these antibodies in blocking experiments is based on prior evidence that they do not have known
specificity towards laminin receptors on PC-3 cells. In these experiments, PC-3 cells were pre-treated with both
the antibodies separately followed by treatment with MGF-AuNPs for 60 min. Post incubation, the dark field
microscopic and TEM analysis of tumor cells indicated that these antibodies failed to block the endocytosis of
MGF-AuNPs within PC-3 cells (Fig. 2E,F,I,J). In fact, the high propensity of endocytosis of MGF-AuNPs into
PC-3 cells, post incubation with anti-fibronectin AB (Fn-3), and mouse IgG Isotype, was very similar to the
results we have observed with the unblocked PC-3 cells (Fig. 2A). These detailed cellular interrogation investigations, as described above, clearly establish that MGF-AuNPs target laminin receptors on prostate tumor cells and
thus reinforce their prospects for applications in the treatment of prostate and related tumors.

Clathrin vs caveolae‑mediated endocytosis and cell trafficking pathways of MGF‑AuNPs. In
order to understand the precise nature of the interaction MGF-AuNPs with prostate cellular (PC-3) membrane,
we have explored further on the mode of endocytosis using two independent techniques involving dark field
microscopy and transmission electron microscopy (TEM). The internalization and uptake of MGF-AuNPs with
PC-3 cells were studied by incubating nanoparticles at various dilutions at select time points. Microscopic analysis of tumor cells, post incubation periods, revealed that MGF-AuNPs bind to prostate cell membrane within
30 min and internalize into the cells within 60 min of incubation time (Fig. 3A–F). Once the nanoparticles are
accumulated on the cell membrane, these tumor cells appear to form a cavity like structure on the cell membrane
to engulf the AuNPs (Fig. 3C). These detailed time dependent studies suggested that MGF-AuNPs internalize
into the tumor cells presumably through clathrin/caveolae mediated endocytosis. Generally, clathrin and caveolae mediated endocytosis follow receptor-mediated tumor-specific pathway whereas phagocytosis or pinocytosis follow non-specific pathways. In order to confirm that MGF-AuNPs are internalized through clathrin and/
or caveolae mediated tumor specific endocytosis, and not through the non-specific phagocytosis or pinocytosis
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Figure 2.  Clathrin mediated endocytosis of MGF-AuNPs (A–F): Dark field (CytoViva) microscopic images;
(G–J): TEM Images showing PC-3 cells pretreated with Chlorpromazine, anticlarthrin AB, anti-caveolae AB,
anti-fibronectin AB, and mouse IgG Isotype control AB, followed by treatment with MGF-AuNPs (41 µM).
Images infer clathrin dependent and caveolae independent pathways for the endocytosis of MGF-AuNPs in
PC-3 cells.
pathways, we performed additional experiments involving pre-blocking clathrin coated pit using ‘chlorprompazine (CPZ)’ reagent followed by incubation with MGF-AuNPs. Microscopic examinations of tumor cells from
these clathrin blocking experiments revealed that significantly lower quantitates of MGF-AuNPs are internalized into tumor cells as shown in Fig. 2B,C,G. These results clearly suggested that the mechanism of cell surface receptor uptake, and subsequent internalization of MGF-AuNPs, is mediated through clathrins. This is an
important observation because clathrin mediated endocytosis are primarily responsible for subsequent intracellular downstream signaling and modulation of endocytic trafficking (discussed in subsequent sections)78,79. Our
observations of clathrin-mediated endocytosis of MGF-AuNPs is of vital significance in prostate tumor therapy
because recent investigations have shown that clathrin-mediated internalization of Cadherin-11 (Cad11) regulates surface trafficking of Cad11. It is well-known that Cadherin-11 cell adhesion molecule plays an important
role in prostate cancer cell migration and that migratory function of Cad11 in prostate cancer cells is regulated
through dynamic turnover of Cad1179.
We further focused our attention to test if MGF-AuNPs are also following caveolae-mediated pathway for
internalization within prostate tumor cells. Several pre-clinical and clinical investigations have suggested that
expression of Caveolin-1 (Cav-1), an integral membrane protein expressed in two isoforms (Cav-1α and Cav-1β),
as a significant prognostic marker for prostate c ancer80. Cav-1 is overexpressed in prostate cancer cells and is
associated with the progression, cell survival and angiogenic activities of the d
 isease81. Therefore, we reasoned
to explore if the efficient endocytosis of MGF-AuNPs, as depicted in Fig. 2D,H, is mediated through caveolae
pathway. Towards this objective, we performed experiments to first block caveolae on prostate tumor cells by
incubating them with Anti-Caveolin-1 antibody. Post blocking of caveolae on prostate tumor cells, we incubated
these cells with MGF-AuNPs and subsequently performed detailed microscopic analysis. Dark field microscopic
images of PC-3 cells with and without caveolae blocking, as shown in Fig. 2D,H, suggested little/no difference,
between the pre and post caveolae blocking, in the amounts of nanoparticles that were internalized. These findings, therefore, revealed that the mechanism of endocytosis of MGF-AuNPs in PC-3 cells is not mediated through
caveolae expression and indeed occurs primarily through clathrin mediation as described above.
Tumor targeting capabilities of MGF-AuNPs, as shown through extensive prostate tumor cell trafficking
assays outlined above, prompted us to test the potential toxicity of these nanoparticles toward normal cells. The
results are summarized in the following sections.
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Figure 3.  Time dependent internalization of MGF-AuNPs (41 µM) into PC-3 cells, images observed by TEM.
(A) At 30 min; (B,C) at 60 min; (D,E) at 90 min; (F) at 120 min.

Interaction of MGF‑AuNPs with normal cells. In order to elucidate that MGF-AuNPs are tumor cell
specific and that they have minimal or no affinity toward normal cells, we have further evaluated cellular interaction of MGF-AuNPs using human aortic endothelial cells (HAECs). We hypothesized that MGF-AuNPs selectively target prostate tumor cells due to their overexpression of laminin receptors and that they cause minimal/
no toxicity to normal cells because normal cells exhibit minimum laminin receptor density82. Therefore, we
incubated MGF-AuNPs with endothelial cells (HAECs) and looked for the uptake of gold nanoparticles in these
cells through electron microscopy. The results presented in Fig. 4A,B, confirmed that HAECs showed minimum
uptake of MGF-AuNPs at the same dose and time point (41 µM; 60 min incubation) as was used for similar
experiments with prostate tumor cells (PC-3). These results are of profound importance in the context of various applications of MGF-AuNPs as a tumor specific therapeutic agent with minimal/no toxicity to normal cells.
These detailed cellular interrogation investigations, as described above, have clearly established that MGFAuNPs target laminin receptors on prostate tumor cells and that they exhibit minimal/no toxicity to normal
cells. Exploring the effects of MGF-AuNPs on prostate tumor and normal HAECs cell viability was the next
logical step in our quest to validate the applicability of MGF-AuNPs as a tumor specific nanomedicine agent.
Effects of MGF‑AuNPs on prostate tumor and normal HAECs cell viability.

We have performed
MTT assays to evaluate viability of prostate tumor and HAECs cells upon treatment with MGF-AuNPs. Choice
of PC-3 cells was rationalized based on their innate metastatic nature. Serial dilutions of MGF-AuNPs were prepared in RPMI media to treat with PC-3 cells. The cell viability profiles, as shown in Fig. 5A, inferred that these
nanoparticles exhibited dose dependent efficacy for causing death of cancer cells. Figure 5A depicts increased
reduction in cancer cell viability with increasing concentrations of the MGF-AuNPs agent over a period of 48
and 72 h. At each of the concentrations, we observed reduced cell viability as compared to the control untreated,
and a significant reduction of tumor cells was noted at a concentration of 165 µM and beyond. Starch stabilized
gold nanoparticles (S-AuNPs) as well as Gum-Arabic stabilized gold nanoparticles (GA-AuNPs) were used as
control NPs group for the in vitro experiments in all the cell viability assays to demonstrate minimal/no effect of
control group of nanoparticles on cells (For details, see supplementary materials section; Figure S5).
In summary, MTT cell viability assay for prostate tumor cells and normal cells (Fig. 5A,B), taken together, with
results from control group of gold nanoparticles (Figure See supplementary materials section; Figure S5), demonstrated that MGF-AuNPs presented dose limiting selective toxicity to tumor cells with no effect on normal cells.

Evaluation of induction of apoptotic vs necrotic cancer cell death patterns of MGF‑AuNPs on
PC‑3 cells. We wanted to test if the mechanism of tumor cell death, when MGF-AuNPs interacted with
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Figure 4.  TEM images showing minimal uptake of MGF-AuNPs into human aortic endothelial cells (HAECs),
60 min post treatment of MGF-AuNPs (41 µM). (A) HAECs cells control; no treatment; (B) MGF-AuNPs
treated cells (41 µM).

Figure 5.  MGF-AuNPs inhibit the proliferation of PC-3 cells and not HAECs. (A) PC-3 cells were cultured in
96 well plates overnight for adherence and rest. The cells were treated with indicated doses of MGF-AuNPs and
for 48 and 72 h. MTT assay was performed at the end of the treatment. (B) HAECs were cultured overnight in
96 well plates for rest and adherence. The cells were treated MGF-AuNPs for indicated times and doses. MTT
assay was performed at the end of the treatment.
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Figure 6.  MGF-AuNPs produced apoptosis in PC-3 cells and inhibits endothelial cell tube formation: (A,B)
PC-3 cells were cultured in 6 well plates for overnight followed by treatment with MGF-AuNPs for 24 h. The
cells were harvested and permeabilized. After permeabilization the cells were stained with Annexin V for
membrane damage and with Propidium Iodide (PI) for DNA damage. The cells were washed and analyzed by
either flow cytometry or fluorescent microscopy; (C) 6 well plates were layered with Matrigel and HAECs were
cultured on the Matrigel for tube formation. AuNPs at 41 and 83 µM for 24 h were added to the culture. Tube
formation was observed under the light microscope and pictures were taken.

PC-3 cells, is driven through a regulated programmed cell death (apoptosis), or through a passive, uncontrolled
necrosis course. Apoptotic cells are measured by their cell membrane disruption, chromatic condensation, and
DNA degradation which leads to cell death. In our assays, we used flow cytometry and fluorescent microscopic
techniques to visualize patterns of early and late apoptosis by PI and FITC-Annx V staining. Cells with early
apoptosis are FITC (+ ve) and PI (− ve), whereas cells at late apoptotic stages are FITC (+ ve) and PI (+ ve). Our
results have confirmed that PC-3 cells treated with MGF-AuNPs showed 40% total cell death including early and
late-stage apoptosis at a dose of 83 µM compared to untreated controls (14.38%) (Fig. 6A) which is 278% more
than the control cells. These results provide important insights that MGF-AuNPs exert apoptotic influence on
PC-3 cells in tumor selective therapy. We have further verified, the Annexin V/PI assay results, through careful observations of cellular morphology of PC-3 cells upon treatment with MGF-AuNPs. The results presented
in Fig. 6B indicated that cells treated with MGF-AuNPs exhibited significantly more apoptosis compared to
untreated control cells. Early apoptotic cells are colored in green whereas late stage apoptotic and/or necrotic
cells are colored in red (Fig. 6B). It may be discerned, from Fig. 6A,B that more cells were found in early and
late apoptotic stages, in the MGF-AuNPs treatment group, as compared to the untreated control group. It is also
significant to recognize that MGF-AuNPs, at the dose of 83 µM, showed almost similar pattern of apoptotic cells
death as was observed upon treatment of cancer cells with the standard drug ‘Staurosporine’ (Fig. 6B). In summary, all our results, taken together, unequivocally, confirmed that MGF conjugated-AuNPs induced apoptosis
of cancer cells through early-stage apoptotic phase, and finally resulting in effective programmed cancer cell
death.

Anti‑angiogenesis activity of MGF‑AuNPs. Angiogenesis plays a vital role in the overall growth pro-

cess of cancers as it dictates the migration and differentiation of endothelial cells, which line the inside wall of
blood vessels83. Chemical signals in the body control the rapidity of angiogenesis by providing efficient blood
supply that stimulate angiogenesis as well as stimulate nearby normal cells to produce angiogenesis signaling
molecules84. The ligand-receptor pairs such as vascular endothelial growth factor (VEGF)-VEGFR (receptor),
platelet derived growth factor (PDGF)-PDGFR, fibroblast growth factor (FGF)-FGFR, and epidermal growth
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factor EGF-EGFR affect the angiogenesis85. Therefore, angiogenesis inhibiting agents are pivotal in the effective
treatment of various cancers, particularly the solid tumors. We have, therefore, performed additional studies to
elucidate the anti-angiogenesis capabilities of MGF-AuNPs through capillary tube structures formation assay.
Phase contrast microscopic images, as depicted in Fig. 6C, clearly showed that the HAECs cells, pre-incubated
with MGF-AuNPs nanomedicine agent, at 41 and 83 µM doses effectively inhibited the formation of capillaries
as compared to the control untreated group, where the complete vasculature structure was seen intact (Fig. 6C).
Angiogenesis plays a critical role in the growth of cancers because solid tumors need blood supply if they are to
grow beyond a few millimeters in s ize83. Tumors can actually cause this blood supply to form by giving off chemical signals that stimulate angiogenesis. Tumors can also stimulate nearby normal cells to produce angiogenesis
signaling molecules84. Vinblastine has emerged as an effective microtubule destabilizing agent because of its
ability to target tubulin, thus inhibiting its polymerization and the subsequent association of microtubules. The
superior antiangiogenic features of vinblastine restrain the tumor growth while decelerating malignant angiogenesis in a vast majority of human c ancers86,87. Therefore, we have compared the antiangiogenic characteristics
of MGF-AuNPs with the FDA approved vinblastine. Our results, as depicted in Fig. 6C, compellingly infer that
the anti-angiogenesis effects of MGF-AuNPs are comparable with the FDA approved drug vinblastine. These
findings provide compelling evidence on the vast potential of MGF-AuNPs for use as an anti-angiogenesis agent
in oncology.

Role of nuclear factor kappa B (NF‑κB) transcription factor in prostate cancer.

In the context
of prostate cancer, several clinical investigations, involving human prostate cancer patients, have shown strong
correlations between increased frequency of NF-κB p65 and a risk of disease p
 rogression88. Indeed, the identification of patients with high-risk prostate cancer (PC) and its direct association with the nuclear localization
of NF-κB p65, from cohorts of patients, has generated considerable interest in the tremendous prognostic clinical value of this cell signaling pathway as a potential prognostic parameter in gauging treatment outcomes of
advanced stage prostate cancer p
 atients89. Therefore, we have probed the potential utility of MGF-AuNPs as a
NF-κB targeting agent through interactions with PC-3 prostate tumor cells from the human prostate tumor
origin.

MGF‑AuNPs target nuclear factor kappa B (NF‑κB) transcription factor. Nuclear factor kappa B
(NF-κB) constitute a family of genes acting in concert in malignant tumor invasion, migration and metastasis,
of various human cancers including breast, colon, lung, oral, pancreatic, and prostate cancers90,91. Several investigations have inferred that (NF-κB) activation is directly responsible for the cross talk between inflammation
and cancer progression92. The remarkable interrelationship of NF-κB activation to tumor progression—through
a combination of processes including tumor cell proliferation, retarding apoptosis, accelerating angiogenesis,
promoting pro-tumor macrophages—singularly and collectively underscore the importance of developing new
therapeutic agents that target NF-κB both for the prevention as well as for the treatment of various human
cancers92,93. We have, therefore, undertaken evaluations to examine if MGF-AuNPs can efficiently suppress the
activation of NF-κB in tumor cells. Our investigations entailed seeding PC-3 cells into 6 well plates with subsequent treatment with MGF-AuNPs. These MGF-AuNPs-treated cells were subsequently post-treated with
tumor necrosis factor alpha (TNF-α) for another 30 min at 37 °C. TNF-α, is a multifunctional pro-inflammatory
cytokine that belongs to the tumor necrosis factor superfamily94. The control group PC-3 cells were incubated
with TNF-α only to stimulate NF-κB95,96. Quantification of NF-κB suppressive effects of MGF-AuNPs was carried out using flow cytometry in comparison with the controls. The flow cytometry analysis, as shown in the supplementary materials in Figure S6, indicated that MGF-AuNPs effectively blocked the TNF-α-induced-NF-kB
activation in the PC-3 cells, which were pretreated with the nanomedicine agent, with subsequent post treatment
with TNF-α. Images depicted in Figure S6 further confirmed that the NF-κB levels were indeed significantly
higher in the PC-3 control group—which were not treated with MGF-AuNPs (Figure S6). These studies highlight two important experimental findings that MGF-AuNPs can be used: (1) for the inhibition of NF-κB signaling thereby transferring signals to the nucleus to induce corresponding gene expression, to control excessive cell
proliferation, reduce/eliminate apoptotic resistance—all resulting in anti-angiogenesis, inhibiting invasion, and
thus to effectively control/eliminate metastasis; and (2) in the overall design of new targeted therapeutics aimed
at cancer prevention and therapy.
TNF-α has gained a ubiquitous “yin and yang” role in cancer development and metastases. It is well-known
that TNF-α released from macrophages activates NF-κB-mediated signaling pathway in various cancers—thus
playing a major role in cancer progression and m
 etastasis94–97. Tumor microenvironment is highly dynamic in
cell-to-cell crosstalk between NF-κB and other signaling pathways. Such crosstalk feedback loops modulate
the inflammatory response in macrophages by altering NF-κB a ctivation98. Encouraged by the NF-κB targeting ability of MGF-AuNPs, we reasoned the logistics of the role of this nanomedicine agent in targeting tumor
microenvironment. A strong rationale for such investigations stemmed from the fact that tumor-associated
macrophages (TAMs) engineer regulation of cancer growth and metastases through alterations of tumor cell
proliferation, migration, invasion, angiogenesis, and immunosuppression. Immune cells outside the tumors
produce pro-inflammatory cytokines to activate tumor NF-κB pathway of tumor cells and also tumor-infiltrating
cells such as macrophages and myeloid-derived suppressor cells (MDSCs)—all resulting in a tumor-permissive
environment for the growth and metastasis.
In the following sections, we will describe the key findings of the innate ability of MGF-AuNPs to target
macrophages and subsequently on how the macrophage affinity of this nanomedicine agent would translate into
the design of a new immunomodulatory prostate cancer therapeutic agent.
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Figure 7.  Macrophages internalize MGF-AuNPs more than PC-3 cells. (A,B) RAW 264.7 and PC-3 were
cultured in 6 well plates for overnight. The cells were then incubated with MGF-AuNPs for 1 h followed by
washing of the cells to remove uninternalized MGF-AuNPs. The cells were then analyzed by CytoViva dark field
microscopy and pictures were taken.

Target specificity of MGF‑AuNPs toward macrophages. In our investigations, RAW264.7 cells
were chosen over bone marrow derived macrophages (BMDMs), for two primary reasons: (1) RAW264.7 are
developed from peritoneal macrophages and are, therefore, more diverse in macrophage population i.e., the
macrophages come from all visceral tissues. Therefore, our overarching objective was to test if MGF-AuNPs
can reeducate macrophages from diverse tissues so that this new nanomedicine agent can be used in treating
tumors of different tissue origin and not just prostate tumors; (2) RAW264.7 cells are not subjected to cytokine
stimulation, which is the case with BMDMs, that puts BMDMs slightly more on pre-activated side, which in
turn might interfere with MGF-AuNPs ability as a macrophage re-education agent. The central hypothesis of our
investigation was to address the ability of the nanomedicine agent, MGF-AuNPs, to re-educate macrophages to
eliminate tumors. It is important to recognize that T cells are not involved in producing the anti-tumor effects in
our investigations because we have used SCID mice which are deficient in T and B cells. Therefore, our in vivo
investigations, as described in subsequent sections provide compelling evidence on the ability of MGF-AuNPs
as a macrophage re-education immunomodulatory agent.
Macrophages are classified as non-neoplastic cells with pro-tumor or anti-tumor phenotypes depending
on their anatomical location, and the physiological context. Classically activated macrophages (referred to
as M1) and alternatively activated macrophages (referred to as M2) fit two extremes within the spectrum of
the macrophage phenotypes99. Tumor-associated macrophages (TAMs) closely resemble “alternative” (M2)
macrophages100. M1 macrophages are recognized as classically activated macrophages that can phagocytize
pathogens and exert tumoricidal activity through activation of antitumor activity primarily by IL-12–dependent
natural killer (NK) cell recruitment. On the other hand, proliferating tumors in humans exhibit polarized M2
phenotype that are directly involved in tumor metastasis, and ultimately contributing to drug resistance of the
disease101. Tumor associated macrophages often express M2-like phenotype with high IL-10, high arginase-1 and
low IL-12—all contributing to pro-tumorigenic activities. In the context of prostate cancer, there is considerable
evidence supporting macrophage infiltrations (inflammation) which are associated with especially advanced
stages of prostate cancer. In fact, castrated tumors possess more pro-tumorigenic M2 macrophage phenotype
thus inducing the onset of immunosuppressive state102–105.
It is also important to note that drugs capable of targeting NF-κB signaling in TAMs can reprogram macrophages from the pro-tumor M2 to an anti-tumor M1 phenotype. This process within the TAMs promotes
regression of advanced tumors by induction of macrophage tumoricidal activity and activation of antitumor
activity through IL-12–dependent NK cell r ecruitment106,107. Given the importance of M2 to M1 macrophage
reeducation and the established role of MGF-AuNPs in targeting NF-κB signaling, the logical next step was
to evaluate the macrophage targeting ability of this nanomedicine agent, especially to explore its capability in
transforming pro-tumor M2 to an anti-tumor M1 phenotype within TAMs.
In our initial experiments, we treated the RAW 264.7 macrophages with MGF-AuNPs and evaluated for
the endocytosis of these nanoparticles in macrophage cells. As shown in Fig. 7, indeed, MGF-AuNPs displayed
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Figure 8.  MGF-AuNPs induced polarization of macrophages and inhibits NF-κB activation. (A–D) RAW
264.7 cells were pretreated with either Starch-AuNPs (S-AuNPs as control), or MGF-AuNPs for 2 h and treated
either with LPS (100 ng/mL) or RANKL (25 ng/mL) or left untreated for 4 h. RNA was isolated from treated and
untreated samples and analyzed for IL-12, TNF-α, IL-10, and IL-6 by real time PCR using probes from TaqMan,
Applied Biosystems. (E). RAW 264.7 cells were either treated with LPS (100 ng/mL) or Starch-AuNPs (S-AuNPs
as control), or MGF-AuNPs or left untreated for 30 min. The cells were lysed with 1X Lamellae buffer and lysates
were run on PAGE gel and transferred onto nitrocellulose membranes. The membranes were than probed for
either phospho- NF-κB or NF-κB using respective antibodies. (F). The RAW 264.7 cells were cultured overnight
in 6 well plates and pre-treated with different doses of MGF-AuNPs (0, 32 µg/mL) for 3 h. Subsequently the cells
were washed and treated with LPS (100 ng/mL) for 45 min. After incubation with LPS the cells were washed,
fixed and permeabilized. After permeabilization the cells were stained with PE conjugated anti-NF-κB antibody
for 45 min. The cells were washed and analyzed using flow cytometry. (G) The RAW 264.7 cells were cultured
overnight in 6 well plates and pre-treated with different doses of MGF-AuNPs (0, 32 µg/mL) for 45 min. Cells
were fixed, permeabilized and stained with PE conjugated anti-NF-κB antibody for 1 h and analyzed by flow
cytometry.
excellent affinity and propensity to internalize within macrophages through phagocytosis. It is important to
note that comparison of images (Fig. 7A,B), demonstrates that, under similar experimental conditions of using
MGF-AuNPs (40 µM) incubated for 60 min, macrophages assimilated higher payloads of MGF-AuNPs as compared to PC-3 cells. Macrophages phagocytized MGF-AuNPs efficiently, whereas the PC-3 cells, which use
laminin receptor-mediation as the primary process to internalize these nanoparticles, exhibited significantly
lower propensity for internalization of this nanomedicine agent. Having established the macrophage-avidity
of MGF-AuNPs, we turned our attention in testing the ability of these nanoparticles in inhibiting NF-κB phosphorylation in macrophages.

MGF‑AuNPs inhibit NF‑κB phosphorylation in macrophages.

NF-κB is a transcription factor that
resides in IκB kinase (IKK) complex located in the cytoplasm along with inhibitor of NF-κB proteins (IκBs),
NF-κB activation is stimulated by TNF-α, or other cell stressors which then leads to NF-κB phosphorylation and
translocation to the nucleus89. This directly influences the transcription of pro-tumor genes in cancer cells and
macrophages. The rationale for our investigations is that the NF-κB intervention in macrophages can polarize
macrophages to the anti-tumor M1 phenotype to eliminate tumors100. In order to evaluate the ability of MGFAuNPs to induce NF-κB inhibition in macrophages, we pretreated RAW 264.7 with either MGF-AuNPs or starch
encapsulated AuNPs (Starch-AuNPs: S-AuNPs served as a control AuNPs). Our experimental findings revealed
that MGF-AuNPs inhibited RANKL and LPS induced NF-κB in macrophages (Fig. 8E,F).
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Figure 9.  MGF-AuNPs-treated macrophages inhibited the proliferation of prostate tumor cells. Raw 264.7
macrophages were pre-treated with MGF-AuNPs for 18 h. Separately, PC-3 cells were labelled with CFSE to
assess their proliferation. The macrophages were then co-cultured with PC-3 cells for 72 h. The images were
obtained by fluorescent microscope.

MGF‑AuNPs, but not S‑AuNPs, polarize macrophages to anti‑tumor or M1 phenotype. Tumor
microenvironment modifies the macrophages which then aid in the progression of these tumors108. The modified macrophages or TAMs have reduced antigen presentation ability and produce elevated levels of immunosuppressive cytokines such as IL-10108. The macrophages within the tumor microenvironment also produce
increased levels of antiangiogenic cytokines such as IL-6109. In order to understand the effects of MGF-AuNPs on
macrophages, we have investigated the expression of macrophage polarizing cytokines such as IL-12, IL-10, IL-6,
and TNF-α upon treating RAW 264.7 macrophages with MGF-AuNPs. In RAW 264.7 macrophages, which were
treated with MGF-AuNPs, our experimental findings conclusively demonstrated elevated levels of anti-tumor
cytokines such as IL-12 and TNF-α, while reducing the levels of pro-tumor cytokines such as IL-10 and IL-6
(Fig. 8A–D). In contrast, the results from similar investigations using the starch-stabilized gold nanoparticles
(S-AuNPs), we observed no macrophage targeting capability and no influence in elevating the levels of antitumor cytokines such as IL-12 and TNF-α (Fig. 8). These results suggested the potential immunotherapeutic
role of MGF-AuNPs and, therefore, prompted us to further probe into capabilities of this nanomedicine agent
for modifying macrophages.
In order to evaluate if MGF-AuNPs can reprogram M2 macrophages into the therapeutically desirable anticancer M1 phenotype, we cocultured MGF-AuNPs-pretreated macrophages with prostate tumor cells (PC-3) and
then looked for tumor proliferation differences between this group and the control PC-3 cells which were directly
treated with naïve macrophages only (Scheme 3). We found that macrophages transfected with the MGF-AuNPs
agent displayed gene expression profiles similar to anti-tumor M1 phenotype. This observation is consistent with
the significant inhibition in the proliferation of tumor cells. However, PC-3 cells that were cocultured with naïve
macrophages failed to reduce the proliferation of PC-3 cells (Fig. 9 and Scheme 3). These data suggest that MGFAuNPs-mediate anti-tumor phenotype to macrophages expression and therefore warranted further investigations
on whether this nanomedicine agent would promote elevation in the levels of anti-tumor cytokines such as IL-12
and TNF-α while reducing the levels of pro-tumor cytokines such as IL-10 and IL-6. With this objective in mind,
we incubated MGF-AuNPs with RAW 264.7 macrophages and analyzed the levels of various pro-tumor and antitumor cytokines. Real-time PCR (Quantitative-PCR) showed robust increase in anti-tumor (pro-inflammatory)
cytokines IL-12 (tenfold higher) and TNF-a (50-fold higher), while reducing the levels of pro-tumor cytokines
such as IL-10 and IL-6 in macrophages treated with MGF-AuNPs. Similar experiments using the starch-stabilized
gold nanoparticles (S-AuNPs) control showed no effects toward enhancing anti-tumor cytokines in the treated
macrophage cells (Fig. 8). Tumor microenvironment modifies the macrophages which then aid in the progression
Scientific Reports |
Vol:.(1234567890)

(2021) 11:16797 |

https://doi.org/10.1038/s41598-021-96224-8

14

www.nature.com/scientificreports/

Scheme 3.  Targeting ability of MGF-AuNPs toward tumor microenvironment (TME) and it’s reprograming
ability of M2 to M1 phenotype.
of these t umors102. The modified macrophages or TAMs have reduced antigen presentation ability and produce
elevated levels of immunosuppressive cytokines such as IL-10108. The macrophages within the tumor microenvironment also produce increased levels of antiangiogenic cytokines such as IL-6. Therefore, our results which
demonstrate the ability of MGF-AuNPs in promoting higher levels of anti-tumor cytokines, such as IL-12 and
TNF-α, while reducing the levels of pro-tumor cytokines, such as IL-10 and IL-6, are significant toward proving
the immunomodulatory intervention in prostate cancer therapy (Scheme 3).
TAMs which originate from resident macrophages from the bone marrow and spleen are key tumor stromal
cell types and play a critical role in tumor survival, growth, and m
 etastasis110,111. Several investigations have confirmed spleen macrophages (Mφ) as the key TAM precursors, where macrophages maintain hematopoietic steady
state by engulfment of neutrophils and eosinophils112. Tumor microenvironment modifies the macrophages
which then aid in the progression of these tumors. The modified macrophages or TAMs have reduced antigen
presentation ability and produce elevated levels of immunosuppressive cytokines such as IL-10. The macrophages
within the tumor microenvironment also produce increased levels of antiangiogenic cytokines such as IL-6. It
is important to understand how enhanced retention of MGF-AuNPs in spleen affects macrophage function.
In order to explore the ability of MGF-AuNPs to target splenic macrophages, we have undertaken a detailed
biodistribution study of MGF-AuNPs in normal mice as discussed below.

Targeting splenic macrophages. Spleen is a critical secondary lymphoid organ showing abundance
of B cells, T cells, NK cells, and is also a reservoir of mononuclear phagocyte system (MPS), mainly resident
macrophages113. Recent investigations have shown that the local and systemic immune response to cancer
increases by the ability of drugs or nanoparticles to target splenic macrophages which comprise mostly of
M2-like pro-tumor macrophages114. Macrophage position and function in splenic domains confer them unique
phenotypes115. Suzuki et al. have shown that Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid
suppressor cells in tumor-bearing animals and enhances antitumor immune activity116. Indeed, the superior
antitumoral efficacy of Trabectedin (Yondelis) has been attributed to the ability of this drug to target splenic
macrophages thus exerting TAM selective cytotoxic activity towards Ly6Chigh monocytes in circulation and in
the spleen117. In order to evaluate further on the macrophage targeting ability and immunomodulatory characteristics of MGF-AuNPs, we have performed systemic administration via intravenous injection in mice—all
aimed at testing if this nanomedicine agent is effective in targeting splenic macrophages. We discuss here compelling evidence from murine models of cancer in support of macrophage-targeted intervention strategies with
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Figure 10.  MGF-AuNPs preferentially accumulate in spleens of SCID mice: (A) Biodistribution of MGF198
AuNPs in normal mice showing selective uptake only in liver and spleen and limited/no uptake in non-target
organs; (B) Biodistribution of MGF-AuNPs in prostate tumor bearing SCID mice. Gold concentrations in
tumor, liver and spleen measured using neutron activation analysis (NAA)—showing limited uptake in tumors
and major uptake in spleen and liver—suggesting targeting of MGF-AuNPs on splenic macrophages.
the potential of MGF-AuNPs for use in dramatically reducing prostate and various other cancer morbidities
through immunomodulatory mechanisms.
In order to understand the pharmacokinetics/ pharmacodynamics of MGF-AuNPs, we have evaluated the
uptake of gold nanoparticles, in vivo, in normal mice as well as in prostate tumor-bearing mice. These studies
were performed by first producing the radioactive equivalent of MGF-AuNPs using 198Au isotope because the
gamma emission (0.411 MeV) of 198Au isotope allows scintigraphic counting of radioactivity of gold for accurate
estimation of the nanomedicine agent in various organs39. Post administration of radioactive MGF-198AuNPs,
in normal mice, through intravenous delivery, we analyzed for the presence of gold in various organs at various
time points using scintigraphy counting (Fig. 10A)39. Further quantification of gold nanoparticles in spleen, liver
and tumors were performed through neutron activation analysis (NAA) of various organs post administering
specific amounts of MGF-AuNPs (Fig. 10B). Our results, as shown in Fig. 10A,B, showed a significant uptake of
MGF-198AuNP in spleen. This observation is clearly in stark contrast to a vast variety of gold nanoparticles, which
generally show hepatobiliary uptake in liver34,118. Together with these results, we infer the inherent propensity
of MGF-AuNPs to target splenic macrophages.
It may be noted that the mode of delivery, going from the intravenous to intraperitoneal, did not reduce
the uptake of MGF-AuNPs in splenic macrophages. The preferential accumulation in liver and spleen invoked
the possibility of this nanomedicine agent to target splenic macrophages. In order to elucidate if the uptake of
MGF-AuNPs in spleen is indeed of splenic macrophage origin, we have performed further in vivo investigations
using severely combine immune-deficient (SCID) mice. The rationale for this animal model is based on the
fact that SCID mice manifest active macrophages while lacking in T and B c ells119. Before moving onto in vivo
tumor studies with MGF-AuNPs, we tested the toxicity of this nanomedicine agent on SCID mice. The doses of
MGF-AuNPs, at which prostate tumors are suppressed in vivo, caused no systemic toxicity in normal mice as
elucidated through detailed toxicity studies (see supplementary materials section). Intraperitoneal administration
of MGF-AuNPs in SCID mice resulted in preferential accumulation in liver and spleen which further suggested
that MGF-AuNPs might be assimilated by splenic macrophages (Fig. 10). Macrophages play important role in
tumor development by supporting vascularization of tumors as well as inhibition of subsequent generation of
tumor specific cytokines. It is well-known that macrophages migrate to spleens to phagocytize dead RBCs, and
therefore, the accumulation of MGF-AuNPs in spleen, as observed, suggests the selective accumulation of this
nanomedicine agent in the macrophages.
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Figure 11.  MGF-AuNPs inhibit PC-3 tumor growth in SCID mice. The SCID mice were divided in groups of
seven mice each and implanted with PC3 cells subcutaneously in the right flanks. The tumors were allowed to
grow till visible and palpable. Once palpable, the mice were randomized and treated with MGF-AuNPs (0.5 mg/
kg, 1.0 mg/kg and 1.5 mg/kg body weight). These experiments were terminated once the untreated control mice
(SCID) were morbid and started to lose weight. The tumor volumes were measured during the course of the
study and plotted.

The in vivo distribution of MGF-AuNPs in SCID and normal mice, which revealed high percentage of accumulation of MGF-AuNPs in spleen, suggested possible macrophage-based internalization. Macrophage position
and function in splenic domains confer them unique phenotypes thus corroborating tumor killing properties
of MGF-AuNPs-pretreated macrophage cells, as observed in the co-culture experiments involving PC-3 cells
(Fig. 9 and Scheme 3). These experimental findings are of significance because they lend experimental evidence
on the unique characteristic of this nanomedicine agent to exploit trophic macrophages to subvert innate and
adaptive immune responses capable of destroying malignant cells.
Targeting NF-κB signaling pathway, induction of polarization of macrophages to anti-tumor phenotype by
inhibiting NF-κB phosphorylation, ability to promote the levels of anti-tumor cytokines, such as IL-12 and TNFα, as discussed above—individually and collectively—infer the immunomodulatory features of MGF-AuNPs.
In vivo therapeutic efficacy studies of MGF-AuNPs in tumor model was an obvious next step to evaluate whether
the various immunomodulatory parameters, as observed in vitro, would be translated under the more complex
in vivo tumor profiles in tumor bearing mice. We have therefore, undertaken detailed therapeutic efficacy of
MGF-AuNPs in prostate tumor bearing SCID mice as discussed below.

Therapeutic efficacy of MGF‑AuNPs in treating prostate tumor.

We have used severe combined
immunodeficient (SCID) male mice bearing a flank model of human prostate cancer, derived from a subcutaneous implant of 10 million PC-3 cells, for the therapeutic efficacy and pharmacokinetic studies. In our evaluations, unilateral solid tumors were allowed to grow for three weeks, and animals were randomized (denoted
Day 0) into control and treatment groups (n = 7) with no significant differences in tumor volume (0.0076 ± 0.08
to 0.0083 ± 0.04 cm3). In vivo dosing involved administering on day 0 three doses of MGF-AuNP (0.5 mg/kg
bw, 1.0 mg/kg bw and 1.5 mg/kg bw—in 100 μL Dulbecco’s PBS) intraperitoneally, while the control SCID mice
received only 100 μL Dulbecco’s PBS/saline. This treatment regimen was performed twice per week. Tumors
were then measured twice each week until the end of the study (Day 42). Figure 11 shows results from the MGFAuNPs-treated human prostate cancer bearing SCID mice. Within two weeks (Day 14), tumor growth in the
treated animals started slowing down with respect to the control animals. Day 17, post administration of MGFAuNPs (1.5 mg/kg bw), tumor volumes were two-fold lower (p < 0.005) for treated animals as compared to the
control group. Three weeks, post administration of after MGF-AuNPs (1.5 mg/kg bw), tumor volumes for the
control animals were fully six-fold greater with respect to those for the MGF-AuNPs-treated group (p < 0.0001;
0.37 ± 0.05 vs. 0.06 ± 0.02 cm3)—suggesting > 85% reduction in the overall tumor volume for the treated group.
This significant therapeutic effect was maintained throughout the 42 days long study. Tumors harvested from the
treatment group consisted largely of necrotic tissue, indicating extensive death of tumor cells.
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Interestingly, biodistribution studies suggested that very low percentage of MGF-AuNPs reached the tumor
tissue while most of the therapeutic agent was found in the spleen (Fig. 10). It is important to note that SCID
mice lack T and B cells which are needed for the growth of human prostate tumors. In this context, the remarkable therapeutic efficacy, as shown in Fig. 11, therefore, suggests the ability of MGF-AuNPs to target the tumor
microenvironment and, thus ensue modification of macrophages as the primary mode of therapeutic action of
this nanomedicine agent.
The above data provides experimental validation to our hypothesis that MGF-AuNPs reeducate the macrophages to eliminate the tumors. It may be noted that the initial antitumor response is based on macrophages
direct interaction with tumor cells and inflammatory cytokine release. These macrophages, after initial interaction with tumor cells, present antigens to T cells. Tumors in most cases modify the macrophages, which then
help in progression of these tumors and suppress the secondary immune response. Therapeutic efficacy data, in
conjunction with immunomodulatory characteristics as discussed in previous sections, demonstrate that our
new therapeutic agent MGF-AuNPs can restore that balance where macrophages reeducation can lead to tumor
growth inhibition. However, in our future investigations, we will be evaluating the effect of MGF-AuNPs on
tumor inhibition using immune-sufficient mice.
The compelling therapeutic efficacy data, as summarized above, was further corroborated through evaluation of angiogenesis inhibitory effects of MGF-AuNPs in vivo. Angiogenesis is ubiquitous in tumor growth,
invasion, progression, and metastasis of a vast majority of human c ancers120. Therefore, targeting this process
may potentially halt the growth and spread of c ancers121. Some of the prominent FDA approved angiogenesis
inhibitors currently used in cancer therapy (with their mode of action) include: Bevacizumab (VEGF-A antibody); Ramucirumab (VEGFR2 antibody); Sunitinib (Tyrosine Kinase Inhibitor); Sorafenib (Tyrosine Kinase
Inhibitor); Pazopanib (Tyrosine Kinase Inhibitor); Lenvatinib (Tyrosine Kinase Inhibitor); and Cabozantinib
(Tyrosine Kinase Inhibitor)121. Angiogenesis inhibitors act through direct interference in blood vessel growth.
A well-established mode of action of angiogenesis inhibitors manifests binding to VEGF and/or its r eceptors122.
Angiogenesis inhibitors are also known to bind to various cell surface receptors, VEGF receptors 1 and 2 which
participate in angiogenesis, or they block blood vessel growth through strong and selective binding interactions
with proteins in the downstream signaling pathways. Our rationale behind these studies stemmed from a variety
of immunomodulatory features of MGF-AuNPs, as discussed in the preceding sections. There is considerable
experimental evidence supporting that angiogenesis inhibitors are immunomodulatory and are capable of suppressing tumor g rowth123 immune system.

Inhibition of angiogenesis in vivo. The compelling immunomodulatory effects, in controlling growth of
tumors in vivo, prompted us to investigate the effects of MGF-AuNPs on angiogenesis in tumor tissues obtained
through in vivo therapeutic efficacy experiments as discussed above. These studies were performed through
immunostaining using the CD31 antibody because it has high specific affinity for vascular endothelial cells.
Twelve fields (at 400x), from each prostate tumor xenografts, were analyzed to determine the average number
of vessels per field (micro-vessel density = MVD). The findings from these studies indicated a significant reduction of MVD in samples collected from the MGF-AuNPs (1.5 mg/kg bw) treated animals as compared to the
control group (saline treated) (Figure S7A–C). Manifestation of angiogenesis in MGF-AuNPs-treated tumor
tissues, taken in concurrence with a plethora of immunomodulatory data discussed above, infers the immunomodulatory angiogenesis inhibitor characteristics of this nanomedicine agent exerting stimulatory effects on
the immune system.

Conclusions

Our studies lend credible experimental evidence demonstrating that inhibition of the receptor activator of NF-κB,
by the new nanomedicine agent MGF-AuNPs, prevents prostate cancer development. The ability of MGF-AuNPs
to target NF-κB signaling pathway will provide an attractive therapeutic strategy for the treatment of various
forms of advanced cancers. As a vast majority of patients with solid tumors require therapeutic approaches with
capabilities to reprogram the local immunosuppressive tumor milieu in order to revive antitumor immunity,
detailed immunotherapeutic investigations, and results reported herein, provide compelling evidence on macrophage targeting abilities of the new MGF-AuNP nanoceutical. Our pre-clinical in vitro and in vivo studies have
shown that MGF-AuNPs effectively target tumor-associated macrophages (TAMs) which abundantly infiltrate
most solid tumors. TAMs-targeting strategies of MGF-AuNPs have been effectively used to initiate macrophage
re-education from pro tumor M2 macrophages to antitumor M1 phenotype—thus eliminating cancer cells,
restrict tumor growth and metastasis. Overall, our green nanotechnology discoveries, which have resulted in the
development of a new generation of phytochemical-encapsulated nanomedicine agent (MGF-AuNP), provide
further new insights on the therapeutic potential of TAM targeting nanoceuticals to improve immunotherapies.

Methods

Materials. Mangiferin, Sodium tetrachloroaurate (III) dihydrate, MTT (3-(4,5-dimethyl thiazol-2-yl)2,5-diphenyl tetrazolium), dynasore reagent and Chlorpromazine (CPZ) were obtained from Sigma (St. Louis,
MO, USA). RPMI, fetal calf serum, TryplE, Trypan blue, DAPI (4′,6-diamidino-2-phenylindole), 2,7-dichlorofluorescin diacetate (DCFH-DA), mouse IgG isotype control, and laminin receptor antibody (MLuC5) were
obtained from ThermoFisher Scientific, USA. FITC Annexin V Apoptosis Detection Kit was obtained from BD
Pharmingen, USA. X-22 anti-clathrin antibody (ab2731), anti-Caveolin-1 antibody (ab2910), anti-fibronectin
antibody (ab18265), and in vitro angiogenesis assay kits (ab204726) were obtained from Abcam, USA. GFPCERTIFIED Apoptosis/ Necrosis detection kit (ENZ-51002) was obtained from Enzo Life Sciences, Inc., USA.
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Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb (Alexa Fluor488 Conjugate) Kit was obtained from Cell Signaling Technology, USA. Double distilled water was used throughout the experiment.

Cell lines. The human prostate cancer (PC-3), human aortic endothelial cells (HAECs), and mouse macrophages (RAW 264.7) cell lines were obtained from the American Type Culture Collection (ATCC; Manassas,
VA), and cultured by the University of Missouri Cell and Immunobiology Core facility using procedures recommended by ATCC. Recent gene therapy results, using in vitro and in vivo models, unequivocally suggest that
PC-3 cells are excellent models for investigations related to drug targeting approaches for treating castrationresistant prostate cancer (CRPC)124–131.
Synthesis of Mangiferin conjugated gold nanoparticles (MGF‑AuNPs). The Mangiferin gold nanoparticles (MGF-AuNPs) were produced by mixing of 4.2 mg mangiferin (MGF) in 6 mL of doubly deionized
(DI) water. The solution was stirred at 100 °C for 10 min to dissolve the MGF into water to get a clear solution132.
Sodium tetrachloroaurate (100 µL of 0.1 M) was added to the reaction mixture to produce gold nanoparticles
(AuNPs). Change in color from yellow to burgundy wine red indicated the formation of MGF-AuNPs in the
homogeneous reaction mixture. The MGF-AuNPs were characterized by various instrumentation techniques
including, UV–Vis spectrophotometry133, Zetasizer Nano S90, T
 EM134 and ICP-MS135. For various in vitro and
in vivo investigations, the treatment concentrations were calculated based on the amount of gold present in
MGF-AuNPs. The amount of Au was calculated by ICP-MS technique136.
Cellular internalization and trafficking pathway. The endocytosis mode of MGF-AuNPs was investigated by pre-blocking various receptors onto PC-3 cells. The optimum dose and incubation time were determined by incubating PC-3 cells with various concentrations of Mangiferin conjugated gold nanoparticles (MGFAuNPs) at different time points. Further, the cell trafficking pathway of MGF-AuNPs was evaluated by using
various receptor blocking agents to confirm the clathrin and or caveolae mediated endocytosis. Chlorpromazine
(CPZ) and X-22 anti-clathrin antibodies were chosen to inhibit clathrin-mediated endocytosis. Anti-Caveolin-1
antibody was chosen to block/inhibit caveolae-mediated uptake. Internalization of MGF-Gold nanoparticles
were monitored by two independent techniques: (i) Cytoviva dark field fluorescence microscopy and; (ii) transmission electron microscopy (TEM)134. For the dark field microscopic study, ultra clean and sterile cover slip
was kept in 6 well plate to grow the PC-3 cells. For the study by TEM t echnique134, cells were grown on the plate
without any coverslip.
Briefly, PC-3 cells ( 106/mL) were seeded into 6 well plates in RPMI medium and incubated for 24 h in CO2
incubator at 37 °C. The cells were pre-incubated with the inhibitors as follows: PBS (control), chlorpromazine
hydrochloride (10 µM; 20 min), X-22 anti-clathrin antibody (3 µg/mL; 60 min), anti-caveolin-1 antibody (3 µg/
mL; 60 min), mouse IgG isotype control (10 µg/mL; 60 min), anti-fibronectin antibody (3 µg/mL; 60 min), and
laminin receptor antibody (ABLR) (10 µg/mL; 60 min). The cells were incubated with all the inhibitors in C
 O2
incubator at 37 °C. Post incubation, cells were washed with 1XPBS twice followed by incubation with MGFAuNPs (41 µM) for 60 min in the C
 O2 incubator at 37 °C. The samples were prepared by the following techniques:
Dark field microscopic technique. After incubation, cells were washed 10 times with 1X PBS, and fixed
with 4% paraformaldehyde (PFA) for 10 min in the CO2 incubator at 37 °C. Cells were further washed 2 times
with 1X PBS and slides were prepared by using DAPI nuclear dye and observed under CytoViva dark field
microscope coupled with dual mode fluorescence. Cell morphology was initially observed, followed by the
uptake of nanoparticles. Images were captured via Dage Imaging Software.
TEM technique. After incubation, cells were washed 10 times with 1X PBS, trypsinized and centrifuged

into pellets, and fixed with 2% glutaraldehyde, 2% paraformaldehyde in sodium cacodylate buffer (0.1 M). The
cells were further fixed with 1% buffered osmium tetroxide in 2-Mercaptoethanol buffer and dehydrated in
graded acetone series and embedded in Epon-Spurr epoxy resin. Sections were cut at 85 nm using a diamond
knife (Diatome, Hatfield PA). The sections were stained with Sato’s triple lead stain and 5% aqueous uranyl acetate for organelle visualization. The samples, as prepared above, were examined on JEOL 1400 TEM microscope
(JEOL, Peabody, Mass.) operated at 80 kV at the University of Missouri’s Electron Microscopy Core F
 acility134.
MGF-AuNPs were explored for their selective affinity toward tumor cells by incubating with the same concentrations and time points as used for the normal endothelial cells (HAECs).

Cell viability assay.

The effect of MGF-AuNPs on prostate cancer (PC-3) and normal human aortic
endothelial (HAECs) cells viability was determined using MTT assay (Sigma) over a period of 48 and 72 h. The
intensity of developed color was measured by micro plate reader (Molecular device, USA) operating at 570 nm
wavelength. Percent cell viability was calculated by using the formula: (T/C) × 100, where C = Absorbance of
control, T = Absorbance of treatment. The IC-50 values were calculated using the Origin software137. Starch
stabilized gold nanoparticles (S-AuNPs) as well as Gum-Arbaic stabilized gold nanoparticles (GA-AuNPs) were
used as control NPs group for the in vitro experiments in all the cell viability assay to demonstrate minimal/no
effect of control group on the cells.

Apoptosis assay. PC-3 cells were incubated with MGF-AuNPs for 24 h and the experiment was performed
according to the manufacture’s protocol (FITC Annexin V Apoptosis Detection Kit I). The samples were ana-
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lyzed by FACScan flow cytometry (FACSort, Becton Dickinson, USA). For each sample, 30,000 ungated events
were acquired138.

Assessment of apoptotic and necrotic cell morphology.

PC-3 cells were incubated with MGFAuNPs for 24 h and the experiment was performed according to the manufacture’s protocol (GFP-CERTIFIED)
Apoptosis/ Necrosis detection kit). Briefly, the PC-3 cells after treatment with either MGF-AuNPs or Staurosporin were incubated with the apoptosis and necrosis detection reagent for 10 min. The slides were prepared
and visualized under fluorescent microscope with a dual filter set for Cyanine-3 (Ex/Em: 550/570 nm), 7-AAD
(Ex/Em: 546/647) and GFP/FITC (Ex/Em: 488/514) (Olympus, USA).

In vitro anti‑angiogenesis assay.

In vitro anti-angiogenesis effect of MGF-AuNPs on HAECs cells was
determined using tube formation assay. The test was performed according the manufacture’s protocol (In vitro
angiogenesis assay kit). Briefly, matrigel was coated in 96 well plate and the plates were incubated for 30 min at
37 °C. HAECs cells and test samples were added into the same plates and incubated for 24 h for tube formation
analysis. The images were captured by fluoresce microscope, (Olympus, Center Valley, PA, USA) at 4 × magnification after 24 h139.

NF‑κB measurement. The Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb (Alexa Fluor488 Conjugate
(catalog number 3033) Kit was used to study the effect of MGF-AuNPs on the expression of NF-κB. Briefly, PC-3
cells were seeded into 6 well plate at a density of 1 06 cells/mL and were incubated for 24 h. The cells were treated
with MGF-AuNPs (40 µM) for 18 h and post-treated with TNF-α (0.1 nM) for another 30 min at 37 °C. The
assay was performed as per kit instructions and the results were analyzed by FACScan flow cytometry (FACSort,
Becton Dickinson, USA) with a minimum of 10,000 events being recorded.
Macrophage MGF‑AuNPs uptake studies. RAW 264.7 macrophages were cultured in DMEM + 10%
FBS in a 75 cm2 flask. The cells at a density of 106 were plated in 6 well plates overnight for adherence. The cells
were then replenished with fresh medium and incubated with MGF-AuNPs (40 µM) for 60 min. Cells were then
analyzed for the presence of gold nanoparticles by CytoViva dark field microscopy.
The effect of MGF‑AuNPs on NF‑κB inhibition in RAW 264.7 macrophages. Cells were preincu-

bated with MGF-AuNPs for 2 h followed by treatment with either LPS (100 ng/mL-positive control) or RANKL
(10 ng/mL) for 30 min. Cells were lysed and lysates were run on polyacrylamide gel electrophoresis and transferred onto nitrocellulose membrane. These membranes were then probed with phospho-NF-κB antibody and
NF-κB from Cell Signaling Technologies140.

Flow cytometry for NF‑κB in RAW macrophages. RAW 264.7 cells (a murine monocyte/macrophage
cell line, ATCC) were plated in 6-well culture plates in DMEM culture media (Gibco) supplemented with 10%
fetal calf serum (Sigma-Aldrich) and 1% penicillin–streptomycin and stored overnight at 37 °C and 5% CO2.
The confluent macrophages were then pre-treated with different doses of MGF-AuNPs (0, 8, 16, and 32 µg/mL)
and S-AuNPs (32 µg/mL) for 3 h. Subsequently the cells were washed with DMEM (1%FBS 1% P/S) to remove
uninternalized nanoparticles and then treated with LPS (100 ng/mL) or TNF-α (20 ng/mL) for 45 min in DMEM
(1% FBS 1% P/S). After incubation with LPS or TNF-α, the cells were suspended by scraping and transferred to
5 mL round-bottom polystyrene tubes (Falcon). The collected samples were centrifuged at 1500 rpm for 5 min,
the supernatant was removed, and the cells were fixed with 4% paraformaldehyde in PBS for 15 min at room
temperature. The cells were then washed in PBS, centrifuged at 1500 rpm for 5 min, and the supernatant was
decanted. The cells were permeabilized for 30 min at room temperature in 90% methanol. After permeabilization, the cells were washed and incubated in 100μL of anti-NF-κB p65 (Ser536) antibody (Cell Signaling, 5733)
at 1:50 dilution for 1 h at room temperature in the dark. Samples were centrifuged at 1500 rpm for 5 min, washed
with 2 mL of 1% FBS PBS. Flow cytometry data was acquired using the BD LSRFortessa X-20 Flow Cytometer
and analyzed using Flowjo software.
Cytokine analysis by real time PCR following treatment of RAW 264.7 cells with
MGF‑AuNPs. RAW 264.7 cells were cultured in 6 well plates overnight for adherence followed by the treat-

ment with MGF-AuNPs for 4 h. LPS and Starch stabilized AuNPs (S-AuNPs) were used as positive and negative
control respectively. The cells were lysed, and RNA was isolated using RNA isolation kit from Qiagen (Germantown, MD). RNA was then analyzed for IL-12, TNF-α, IL-10 and IL-6 using real time P
 CR141.

Effect of MGF‑AuNPs treated macrophages on prostate cancer cell proliferation. PC-3 cells at
a density of 105 cells/well were plated in 6 well plate overnight for adherence. Subsequently, RAW 264.7 macrophages were treated with MGF-AuNPs (4 µM) for 18–24 h. The macrophages were washed to remove unbound
MGF-AuNPs in order to avoid the direct effect of MGF-AuNPs on cancer cells. In the meantime, the PC-3 cells
were labelled with carboxyfluorescien succinimidyl ester (CFSE) to assess their proliferation. The macrophages
were then co-cultured with PC-3 cells using a ratio of 10:1 (1 part of PC-3 cells to 10 part of macrophages) for
72 h. The co-culture was observed under the fluorescent microscope and pictures taken. We observed significant
reduction in the proliferation of PC-3 cells when cocultured with macrophages which were pre-treated with
MGF-AuNPs142.
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Animal studies. All in vivo work has been performed at an IACUC approved laboratory and in accordance
with ARRIVE guidelines for animal welfare.
Ethics declarations. All experiments of MGF-AuNPs involving animals were approved by the Institutional

Animal Care and Use Committees of the Harry S. Truman Memorial Veterans Hospital and the University of
Missouri and were performed in accordance with the Guide for the Care and Use of Laboratory Animals under
an IACUC approved protocol number 8767. Severe combined immuno-deficient SCID (ICR-SCID) male mice
show a severe combined immunodeficiency (from Taconic Farms, Hudson, New York) were used for the therapeutic study. The mice used in our investigations weighed 24–27 g.

Description of animal procurement, housing, and grouping. Animals were maintained on a 12 h

light–dark cycle and had access to sterilized standard chow and water ad libidum. Animals were allowed to
acclimate for 7–10 days prior to initiation of work. Human prostate cancer cell line PC-3 was obtained from the
American Type Culture Collection (ATCC; Manassas, VA), and cultured according to ATCC recommendations
by the University of Missouri Cell and Immunobiology Core facility. Small Cell Neuroendocrine Carcinoma
(SCNC) is a hormone resistant aggressive cancer which does not respond to classic androgen therapy. PC-3 is a
SCNC cell line which is highly metastatic and does not express classic hormone receptors and hence are resistant
to hormone therapy. Moreover, the patients treated with hormone therapy tend to relapse of S CNC143–145. Mice
received ear tag identifiers under inhalational anesthesia (isoflurane/oxygen) followed by unilateral, subcutaneous hind flank inoculations of 10 × 106 PC-3 cells suspended in 0.1 mL of sterile Dulbecco’s phosphate buffered
saline (DPBS) and Matrigel (2:1, v:v). Solid tumors were allowed to develop over a period of 3 weeks, and
animals were randomized (Day 0) into control and treatment groups (n = 7) having no significant difference in
tumor volumes (p = 0.64; Student’s t-test) or body weights (p = 0.17). Tumor volumes were estimated from caliper
measurements using the formula V = length × width × depth. On Day 8, animals in the treatment group received
intraperitoneal administrations of MGF-AuNP agent in DPBS (100 μL) while under inhalational anesthesia in
doses as outlined in the following section. Similarly, control animals received 30 μL of saline intraperitoneally.
No significant difference (p = 0.93) in tumor volume or body weight (p = 0.21) was noted between the groups.
Tumor volumes, body weights and health status were then determined twice each week. At the end of the study
(Day 42), mice were euthanized by cervical dislocation, and blood sample was collected by cardiac puncture.
Samples of spleen, liver, tumor, and blood were harvested, weighed and submitted to the University of Missouri
Neutron Activation Analysis (NAA) facility at the University of Missouri Research reactor (MURR) for the
accurate quantification of gold in various tissues by NAA analysis.
NOTE: Although male mice have been selected in our investigations, it is important to note that this is a
xenograft model, thus murine gender is not anticipated to significantly influence tumor biology. Importantly, as
we are studying prostate cancer, the use of male mice only is appropriate.

In vivo bio‑distribution study by neutron activation analysis (NAA). To assess the gold content in
various tissue in SCID mice (n = 7). 1.5 mg/ kg bw of MGF-AuNPs were administered in these mice for seven
weeks, while control mice (n = 7) did not receive any treatment with MGF-AuNPs. Tumor tissue, spleen, liver
and blood were harvested upon euthanization, put into chloridometer sample vials and dried for approximately
48 h at 100–120 °C. Dried tissue mass of approximately 0.5–1.0 g was placed into polyethylene vials (used for
control of counting geometry). We estimated the amount of gold in various tissue samples as described previously through neutron activation analysis (NAA) techniques38.
In vivo therapeutic efficacy study. Antitumor efficacy of MGF-AuNPs was evaluated by using prostate
tumor xenografts in SCID mice as developed above. Briefly, SCID male mice were subcutaneously inoculated
with 10 × 106 PC-3 cells (suspended in 0.1 mL of sterile DPBS and Matrigel (2∶1, v:v)) in the right hind flank under
inhalation anesthesia (isoflurane/oxygen). After inoculation, tumors were allowed to grow for 2–3 weeks, at
which time the tumors were measured by digital caliper measurements and calculated as length × width × height.
The mice were randomly divided into four groups (n = 7/group) with no significant difference in tumor volume,
randomization was generated using the standard = RAND() function in Microsoft Excel, and the day of randomization was considered the day zero of therapy study (Table 1). On day zero, mice were given intraperitoneal
injections as follows: Group 1: saline treated (100 μL); Group 2: MGF-AuNPs treated (0.5 mg/kg bw); Group
3: MGF-AuNPs treated (1.0 mg/kg bw) and Group 4: MGF-AuNPs treated (1.5 mg/kg bw)—all in 100 μL Dulbecco’s PBS. Using this regimen, animals were treated twice per week until the end of the study (42 days). The
animals were monitored for their tumor volume, body weight and health effects until they were sacrificed at the
end of the study. The fifth group (n = 7) was kept as control group (no tumor and no treatment) and served as a
control for complete blood count (CBC) values and body weight measurements. Animals were sacrificed at the
end of study. Measurement of tumor volumes were carried out twice each week until the end of the study (Day
42).
The tissues (spleen, liver, tumor tissue and blood) were isolated from prostate tumor xenografts and were
submitted to the University of Missouri Neutron Activation Analysis (NAA) facility at the University of Missouri
Research reactor (MURR) for the accurate quantification of gold in various tissues by NAA analysis.
Statistical analysis. All experimental data are described as mean ± SEM. Statistical analysis was carried

out using the one-way analysis of variances (ANOVA) using Graph Pad Prism software. P < 0.05 was considered
significant.
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1. For each
experiment provide brief details of study
design including:
(a) The groups being compared, including
control groups. If no control group has
been used, the rationale should be stated
(b) The experimental unit (e.g. a single
animal, litter, or cage of animals)

1. Full details of in vivo Therapeutic efficacy Studies Design (a and b):
All in vivo work has been performed at an IACUC approved laboratory and in accordance with ARRIVE guidelines
for animal welfare. Animal studies were approved by the Institutional Animal Care and Use Committees of the Harry
S. Truman Memorial Veterans Hospital and the University of Missouri and were performed in accordance with the
Guide for the Care and Use of Laboratory Animals under an IACUC approved protocol number 8767
We have over three decades of experience in conducting hypothesis driven cancer research with in vivo models using
tumor bearing SCID mice to minimize discomfort and adverse effects in study animals (both control and treated
animals). Here are a few representative publications where we have outlined similar in vivo investigations which have
been accepted by the global scientific peers:
(1) Ravi Shukla, Nripen Chanda, and Kattesh V. Katti et al.: 198AuNP-EGCg for prostate cancer therapy: Proceedings
of the National Academy of Sciences Jul 2012, 109 (31) 12426–12431; https://doi.org/10.1073/pnas.1121174109
(2) Nripen Chanda, Vijaya Kattumuri, Kattesh V. Katti, et al.: Bombesin functionalized gold nanoparticles show
in vitro and in vivo cancer receptor specificity: Proceedings of the National Academy of Sciences May 2010, 107 (19)
8760– 8765; https://doi.org/10.1073/pnas.1002143107
(3) Nripen Chanda, Para Kan, Kattesh V. Katti, et al.; Radioactive gold nanoparticles in cancer therapy: therapeutic
efficacy studies of GA-198AuNP nanoconstruct in prostate tumor–bearing mice: Nanomedicine: Nanotechnology,
Biology and Medicine, Volume 6, Issue 2, 2010, Pages 201–209, ISSN 1549-9634, https://doi.org/10.1016/j.nano.
2009.11.001
Brief description of in vivo investigations: Male SCID mice (4–5 weeks of age; Taconic Farms, Hudson, NY) were
housed in a temperature and humidity-controlled pathogen-free barrier facility
NOTE: Although male mice have been selected in our investigations, it is important to note that this is a xenograft
model, thus murine gender is not anticipated to significantly influence tumor biology. Importantly, as we are studying
prostate cancer, the use of male mice only is appropriate
Description of animal procurement, housing, and grouping: Animals were maintained on a 12 h light–dark cycle and
had access to sterilized standard chow and water ad libidum. Animals were allowed to acclimate for 7–10 days prior
to initiation of work. Human prostate cancer cell line PC-3 was obtained from the American Type Culture Collection
(ATCC; Manassas, VA), and cultured according to ATCC recommendations by the University of Missouri Cell and
Immunobiology Core facility. Mice received ear tag identifiers under inhalational anesthesia (isoflurane/oxygen) followed by unilateral, subcutaneous hind flank inoculations of 10 × 106 PC-3 cells suspended in 0.1 mL of sterile Dulbecco’s phosphate buffered saline (DPBS) and Matrigel® (2:1, v:v). Solid tumors were allowed to develop over a period
of 3 weeks, and animals were randomized (Day 0) into control and treatment groups (n = 7) having no significant
difference in tumor volumes (p = 0.64; Student’s t-test) or body weights (p = 0.17). Tumor volumes were estimated
from caliper measurements using the formula V = length × width × depth. On Day 8, animals in the treatment group
received intraperitoneal administrations of MGF-AuNP agent in DPBS (100 µL) while under inhalational anesthesia
in doses as outlined in the following section. Similarly, control animals received 100 µL of saline intraperitoneally.
No significant difference (p = 0.93) in tumor volume or body weight (p = 0.21) was noted between the groups. Tumor
volumes, body weights and health status were then determined twice each week. At the end of the study (Day 42),
mice were euthanized by cervical dislocation, and blood sample was collected by cardiac puncture. Samples of spleen,
liver, tumor, and blood were harvested, weighed and submitted to the University of Missouri Neutron Activation
Analysis (NAA) facility at the University of Missouri Research reactor (MURR) for the accurate quantification of
gold in various tissues by NAA analysis

2
(a) Specify the exact number of experimental units allocated to each group, and
the total number in each experiment. Also
indicate the total number of animals used
(b) Explain how the sample size was
decided. Provide details of any a priori
sample size calculation, if done

Details of Sample Size with descriptions for a and b: As outlined above, SCID mice were randomly divided into four
groups (n = 7/group) with no significant difference in tumor volumes
On day zero, mice were administered intraperitoneal injection of MGF-AuNP agent in DPBS (100 µL) (or saline for
the control group) as follows:
Group 1-saline treated;
Group 2-MGF-AuNPs treated (0.5 mg/kg bw); Group 3-MGF-AuNPs treated (1.0 mg/kg bw); Group 4-MGF-AuNPs
treated (1.5 mg/kg bw)
The fifth group (n = 7) was kept as control group (no tumor and no treatment) and served as a control for the evaluation of complete blood count (CBC) values and body weight measurements. Animals were subjected to vaporizer 5%
isoflurane and sacrificed at the end of study (Day 42)
The above-mentioned sample size is based on consultations with our biostatistician who confirmed that a n = 7 in different treatment and control groups, as elaborated above, would provide scientifically credible statistical significance
to our preclinical data

3
(a) Describe any criteria used for including
and excluding animals (or experimental
units) during the experiment, and data
points during the analysis. Specify if these
criteria were established a priori. If no
criteria were set, state this explicitly
Inclusion and
exclusion criteria (b) For each experimental group, report
any animals, experimental units or data
points not included in the analysis and
explain why. If there were no exclusions,
state so
(b) For each analysis, report the exact value
of n in each experimental group

Inclusion criteria: On the choice of the animal model, we have used Male SCID mice in our investigations
NOTE: Although male mice have been selected in our investigations, it is important to note that this is a xenograft
model, thus murine gender is not anticipated to significantly influence tumor biology. Importantly, as we are studying
prostate cancer, the use of male mice only is appropriate
Experimental and control groups:
SCID mice were randomly divided into four groups (n = 7/group) with no significant difference in tumor volumes
On day zero, mice were administered intraperitoneal injection of MGF-AuNP agent in DPBS (100 µL) (or saline for
the control group) as follows:
Group 1-saline treated
Group 2-MGF-AuNPs treated (0.5 mg/kg bw)
Group 3-MGF-AuNPs treated (1.0 mg/kg bw)
Group 4-MGF-AuNPs treated (1.5 mg/kg bw)
The fifth group (n = 7) was kept as control group (no tumor and no treatment) and served as a control for the evaluation of complete blood count (CBC) values and body weight measurements. Animals were subjected to vaporizer 5%
isoflurane and sacrificed at the end of study (Day 42)
There were no exclusions in our investigations. Exclusion criteria: N/A

Continued
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Recommendation

Randomization

Mice received ear tag identifiers under inhalational anesthesia (isoflurane/oxygen) followed by unilateral, subcutaneous hind flank inoculations of 10 × 106 PC-3 cells suspended in 0.1 mL of sterile Dulbecco’s phosphate buffered saline
(DPBS) and Matrigel® (2:1, v:v). Solid tumors were allowed to develop over a period of 3 weeks, and animals were
randomized (Day 0) into control and treatment groups (n = 7) having no significant difference in tumor volumes
4 (a) State whether randomization was used
(p = 0.64; Student’s t-test) or body weights (p = 0.17). Tumor volumes were estimated from caliper measurements
to allocate experimental units to control
using the formula V = length × width × depth. On Day 8, animals in the treatment group received intraperitoneal
and treatment groups. If done, provide the
administrations of MGF-AuNP agent in DPBS (100 µL) while under inhalational anesthesia in doses as outlined in
method used to generate the randomizathe following section. Similarly, control animals received 100 µL of saline intraperitoneally. No significant difference
tion sequence
(p = 0.93) in tumor volume or body weight (p = 0.21) was noted between the groups. Tumor volumes, body weights
(b) Describe the strategy used to minimize
and health status were then determined twice each week
potential confounders such as the order of
All animal facilities at the Harry S. Truman Memorial Veterans Hospital and the University of Missouri, Columbia,
treatments and measurements, or animal/
Missouri, were visited daily by the veterinarian care staff, inspected by the institutional animal care and use commitcage location. If confounders were not
tee members throughout the investigation
controlled, state this explicitly
Mice were examined daily, and removed from the study if unresponsive to supportive care, moribund, if weight
loss is > 20% body weight or if tumor size > 5 cm3 with poor body condition (hunched posture and loss of > 20%
body weight, or easily palpated exoskeleton) or with lassitude with written protocols to euthanatize such animals to
minimize animal discomfort

Our response with section/line number or reason for not reporting

All experiments of MGF-AuNPs involving animals were approved by the Institutional Animal Care and Use Committees (IACUC, protocol number 8767) of the Harry S. Truman Memorial Veterans Hospital and the University of
Missouri were performed according to the Guide for the Care and Use of Laboratory Animals. All animal facilities at
the Harry S. Truman Memorial Veterans Hospital and the University of Missouri, Columbia, Missouri, were visited
daily by the veterinarian care staff, inspected by the institutional animal care and use committee members throughout the investigation
The animal modeling staffs and veterinarians, who conducted our animal experiments, have over 20 years of experience in all aspects of pharmaceutical testing through placebo-controlled, blinded pre clinal investigations in tumor
bearing mice. Such data has formed the basis for seeking approval for Phase 1 trials of various drugs discovered by us
in the past. In the current investigation, as reported in our manuscript, our staff have exercised due care and caution
to perform blinded experiments in prostate tumor bearing xenografts in SCID mice with our nanomedicine agents
MGF-AuNP with saline in controls

Blinding

5. Describe who was aware of the group
allocation at the different stages of the
experiment (during the allocation, the
conduct of the experiment, the outcome
assessment, and the data analysis)

Outcome measures

Outcome measures:
Morbidity: As accepted by the institutional Animal Care and Use Committees (IACUC, protocol number 8767) of
the Harry S. Truman Memorial Veterans Hospital and the University of Missouri Guide for the Care and Use of
Laboratory Animals, we defined morbidity to include any animal where one of the following conditions exists: the
tumor volume exceeds 5 cm3, ulceration of the overlying skin of the tumor is observed, ulceration of the tumor itself
is observed, body weight-loss of more than 20% is noted, and/or significant illness/depression (whether or not related
to the experimental protocol) is observed. Animals exhibiting any signs of morbidity, as defined, will be sacrificed
immediately to minimize and alleviate any unnecessary pain and suffering. Mortality was evaluated by measuring any
differences in the total survival times between groups as a function of study termination time
These studies required 7 mice per experimental group to provide meaningful statistical results based on the expectation of accurately detecting a 20% difference in experimental tumor groups
Hypothesis validation and expected primary outcome: The overall hypothesis was to validate the antitumor characteristics of the experimental nanomedicine agent. The following groups of control and tumor bearing mice were
administered intraperitoneal injections of MGF-AuNP agent in DPBS (100 µL) (or saline for the control group) as
6 (a) Clearly define all outcome measures
follows:
assessed (e.g. cell death, molecular markers, Group 1-saline treated
or behavioral changes)
Group 2-MGF-AuNPs treated (0.5 mg/kg bw)
(b) For hypothesis-testing studies, specify
Group 3-MGF-AuNPs treated (1.0 mg/kg bw)
the primary outcome measure, i.e. the out- Group 4-MGF-AuNPs treated (1.5 mg/kg bw)
come measure that was used to determine The fifth group (n = 7) was kept as control group (no tumor and no treatment) and served as a control for the evaluathe sample size
tion of complete blood count (CBC) values and body weight measurements. Animals were subjected to vaporizer 5%
isoflurane and sacrificed at the end of study (Day 42)
50–80% reduction in tumor volumes in the treated groups, as compared to the control group, with minimal/no
adverse toxic side effects, (Groups 2–4) was the expected outcome of this hypothesis driven investigation
Throughout the study, the animals were monitored for their tumor volume (groups 1–4), body weight and overall
health (group 1–5). Mice were examined daily, and removed from the study if unresponsive to supportive care,
moribund, if weight loss is > 20% body weight or if tumor size > 5 cm3 with poor body condition (hunched posture
and loss of > 20% body weight, or easily palpated exoskeleton) or with lassitude with written protocols to euthanatize
such animals to minimize animal discomfort
At the end of the study (day 42) animals were subjected to vaporizer 5% isoflurane and before being sacrificed and
following samples were collected from group 1–4, blood, tissues (spleen, liver, and tumor)
Blood samples from all groups were used for complete blood count (CBC) values
The tissues (spleen, liver, tumor and blood) were submitted to the University of Missouri Neutron Activation Analysis (NAA) facility at the University of Missouri Research reactor (MURR) for the accurate quantification of gold in
various tissues by NAA analysis

Statistical
methods

7 a. Provide details of the statistical
methods used for each analysis, including
software used. b. Describe any methods
used to assess whether the data met the
assumptions of the statistical approach,
and what was done if the assumptions were
not met

Mortality was evaluated by measuring any differences in the total survival times between groups as a function of
study termination time. These studies required 7 mice per experimental group to provide meaningful statistical
results based on the expectation of accurately detecting a 20% difference in experimental tumor groups
All experimental data are described as mean ± SEM. Statistical analysis was carried out using the one-way analysis of
variances (ANOVA) using Graph Pad Prism software. P < 0.05 was considered significant
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Species-appropriate details:
(a) Male SCID mice (4–5 weeks of age; Taconic Farms, Hudson, NY) were housed in a temperature and humiditycontrolled pathogen-free barrier facility
NOTE: Although male mice have been selected in our investigations, it is important to note that this is a xenograft
model, thus murine gender is not anticipated to significantly influence tumor biology. Importantly, as we are studying
prostate cancer, the use of male mice only is appropriate
Male SCID mice (4–5 weeks of age; Taconic Farms, Hudson, NY) weighing 20–25 g in weight were housed in a
temperature and humidity-controlled pathogen-free barrier facility
(b) Description of animal procurement, housing, and grouping: Animals were maintained on a 12 h light–dark cycle
8 (a) Provide species-appropriate details of and had access to sterilized standard chow and water ad libidum. Animals were allowed to acclimate for 7–10 days
the animals used, including species, strain prior to initiation of work. Human prostate cancer cell line PC-3 was obtained from the American Type Culture
Collection (ATCC; Manassas, VA), and cultured according to ATCC recommendations by the University of Missouri
and substrain, sex, age or developmental
Cell and Immunobiology Core facility. Mice received ear tag identifiers under inhalational anesthesia (isoflurane/
stage, and, if relevant, weight
(b) Provide further relevant information on oxygen) followed by unilateral, subcutaneous hind flank inoculations of 10 × 106 PC-3 cells suspended in 0.1 mL of
the provenance of animals, health/immune sterile Dulbecco’s phosphate buffered saline (DPBS) and Matrigel® (2:1, v:v). Solid tumors were allowed to develop
status, genetic modification status, genoover a period of 3 weeks, and animals were randomized (Day 0) into control and treatment groups (n = 7) having
type, and any previous procedures
no significant difference in tumor volumes (p = 0.64; Student’s t-test) or body weights (p = 0.17). Tumor volumes
were estimated from caliper measurements using the formula V = length × width × depth. On Day 8, animals in the
treatment group received intraperitoneal administrations of MGF-AuNP agent in DPBS (100 µL) while under inhalational anesthesia in doses as outlined in the following section. Similarly, control animals received 100 µL of saline
intraperitoneally. No significant difference (p = 0.93) in tumor volume or body weight (p = 0.21) was noted between
the groups. Tumor volumes, body weights and health status were then determined twice each week. At the end of the
study (Day 42), mice were euthanized by cervical dislocation, and blood sample was collected by cardiac puncture.
Samples of spleen, liver, tumor, and blood were harvested, weighed and submitted to the University of Missouri
Neutron Activation Analysis (NAA) facility at the University of Missouri Research reactor (MURR) for the accurate
quantification of gold in various tissues by NAA analysis
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Full experimental details of all nnimal studies reported in our manuscript:
Ethics Committee Approvals:
All in vivo work has been performed at an IACUC approved laboratory and in accordance with ARRIVE guidelines
for animal welfare. Animal studies were approved by the Institutional Animal Care and Use Committees of the Harry
S. Truman Memorial Veterans Hospital and the University of Missouri and were performed in accordance with the
Guide for the Care and Use of Laboratory Animals under an IACUC approved protocol number 8767
NOTE: We have over three decades of experience in conducting hypothesis driven cancer research with in vivo
models using tumor bearing SCID mice to minimize discomfort and adverse effects in study animals (both control
and treated animals). Here are a few representative publications where we have outlined similar in vivo investigations
which have been accepted by the global scientific peers:
(4) Ravi Shukla, Nripen Chanda, and Kattesh V. Katti et al.: 198AuNP-EGCg for prostate cancer therapy: Proceedings
of the National Academy of Sciences Jul 2012, 109 (31) 12426–12431; https://doi.org/10.1073/pnas.1121174109
(5) Nripen Chanda, Vijaya Kattumuri, Kattesh
V. Katti, et al.: Bombesin functionalized gold nanoparticles show in vitro and in vivo cancer receptor specificity:
Proceedings of the National Academy of Sciences May 2010, 107 (19) 8760– 8765; https://doi.org/10.1073/pnas.10021
43107
(6) Nripen Chanda, Para Kan, Kattesh V. Katti, et al.; Radioactive gold nanoparticles in cancer therapy: therapeutic
efficacy studies of GA-198AuNP nanoconstruct in prostate tumor–bearing mice: Nanomedicine: Nanotechnology,
Biology and Medicine, Volume 6, Issue 2, 2010, Pages 201–209, ISSN 1549-9634; https://doi.org/10.1016/j.nano.2009.
11.001
Justification for the Use of Animals: There are no in vitro tests that can be used to substitute for the complex tumor
microenvironment occurring in vivo when testing experimental candidates for their effectiveness as prostate cancer
therapy agents. Our investigations of therapeutic effectiveness studies, of a new nanomedicine agent, MGF-AuNP,
in vivo using human prostate tumor xenografts in SCID mice are necessary. Therefore, the SCID mice model with
prostate tumor xenografts, as described in our manuscript, represents the most widely accepted and the best model
for pre-clinical evaluations of novel therapeutic strategies ultimately intended for use in treating human prostate
tumor patients
All experiments of MGF-AuNPs involving animals were approved by the Institutional Animal Care and Use Committees (IACUC, protocol number 8767) of the Harry S. Truman Memorial Veterans Hospital and the University of
9 For each experimental group, including
Missouri were performed according to the Guide for the Care and Use of Laboratory Animals
controls, describe the procedures in enough
We have used severely compromised immunodeficient (SCID) mice bearing a flank model of human prostate cancer
detail to allow others to replicate them,
derived from a subcutaneous implant of 10 million PC-3 cells for therapeutic efficacy and pharmacokinetic studies
including:
(from Taconic Farms, Hudson, New York) were used for the therapeutic study. The mice used in our investigations
(a) What was done, how it was done and
weighed 24–27 g
what was used
In vivo bio-distribution study by Neutron Activation Analysis (NAA). To assess the gold content in tissue in SCID
(b) When and how often
mice (n = 7). 1.5 mg/kg bw MGF-AuNPs were administered in these mice for seven weeks, while control mice (n = 7)
(c) Where (including detail of any acclimadid not receive any treatment with MGF-AuNPs. Tumor, spleen, liver and blood were harvested upon euthanization
tization periods)
(vaporizer 5% isoflurane), put into chloridometer vials and dried for approximately 48 h at 100–120 °C. Dried tissue
(d) Why (provide rationale for procedures)
mass of approximately 0.5–1.0 g was placed into polyethylene vials (used for control of counting geometry). We
estimated the amount of gold in various tissue samples as described previously
In vivo therapeutic efficacy study. Antitumor efficacy of MGF-AuNPs was evaluated by developing prostate
tumor model (in SCID male mice). The SCID male mice were subcutaneously inoculated with 10 × 106 PC-3 cells
(suspended in 0.1 mL of sterile DPBS and Matrigel® (2∶1, v:v)) in the right hind flank under inhalation anesthesia
(isoflurane/ oxygen). After inoculation, tumors were allowed to grow for 2–3 weeks, at which time the tumors were
measured by digital caliper measurements and calculated as length × width × height. The mice were randomly divided
into four groups (n = 7/group) with no significant difference in tumor volume, randomization was generated using
the standard = RAND() function in Microsoft Excel, and the day of randomization was considered the day zero of
therapy study. On day zero, mice were given intraperitoneal injections as follows: Group 1: saline treated (100 µL);
Group 2: MGF-AuNPs
treated (0.5 mg/kg bw); Group 3: MGF-AuNPs treated (1.0 mg/kg bw) and Group 4: MGF-AuNPs treated (1.5 mg/
kg bw)—all in 100 µL Dulbecco’s PBS. Using this regimen, animals were treated twice per week until the end of the
study (42 days). The animals were monitored for their tumor volume, body weight and health effects until they were
sacrificed at the end of the study. The fifth group (n = 7) was kept as control group (no tumor and no treatment) and
served as a control for complete blood count (CBC) values and body weight measurements. Animals were sacrificed
at the end of study. Measurement of tumor volumes were carried out twice each week until the end of the study (Day
42). Within two weeks (Day 14), tumor growth in the treated group (with MGF-AuNPs at 1.5 mg/kg bw), appeared to
be slowing with respect to the controls. After 17 days of post administration (dose of MGF-AuNPs at 1.5 mg/kg bw),
tumor volumes were two- fold lower (p < 0.005) for treated animals compared to controls. This significant therapeutic
effect was maintained throughout our observational study. Tumor volumes for the control animals were fully sixseven-fold greater with respect to those for the MGF-AuNPs-treated group (p < 0.0001; 0.37 ± 0.05 vs. 0.06 ± 0.02 cm3)
groups—at three weeks, post administration of after MGF-AuNPs (1.5 mg/kg bw). These observations were indicative of > 85% reduction in the overall tumor volume for the treated group. This profound therapeutic efficacy was
observed throughout the 42 days long study. Tumors harvested from the treatment group consisted largely of necrotic
tissue, indicating extensive death of tumor cells
The tissues (spleen, liver, tumor tissue and blood) were isolated from prostate tumor xenografts and were submitted
to the University of Missouri Neutron Activation Analysis (NAA) facility at the University of Missouri Research reactor (MURR) for the accurate quantification of gold in various tissues by NAA analysis

Our response with section/line number or reason for not reporting

Results

Full description of Results/Summary (taken directly from our manuscript): In our evaluations, unilateral solid
tumors were allowed to grow for three weeks, and animals were randomized (denoted Day 0) into control and treatment groups (n = 7) with no significant differences in tumor volume. In vivo dosing involved administering on day 0
three doses of MGF-AuNP (0.5 mg/kg bw, 1.0 mg/kg bw and 1.5 mg/kg bw—in 100 µL Dulbecco’s PBS) intraperito10 For each experiment conducted, includneally, while the control SCID mice received only 100 µL Dulbecco’s PBS/saline. Tumors were then measured twice
ing independent replications, report: (a)
each week until the end of the study (Day 42). Figure 11 shows results from the MGF-AuNPs-treated human prostate
Summary/descriptive statistics for each
cancer bearing SCID mice. Within two weeks (Day 14), tumor growth in the treated animals started slowing down
experimental group, with a measure of variwith respect to the control animals. Day 17, post administration of MGF-AuNPs (1.5 mg/kg bw), tumor volumes
ability where applicable (e.g. mean and SD,
were two-fold lower (p < 0.005) for treated animals as compared to the control group. Three weeks, post administraor median and range). (b) If applicable, the
tion of after MGF-AuNPs (1.5 mg/kg bw), tumor volumes for the control animals were fully six-fold greater with
effect size with a confidence interval
respect to those for the MGF-AuNPs-treated group (p < 0.0001; 0.37 ± 0.05 vs. 0.06 ± 0.02 cm3)—suggesting > 85%
reduction in the overall tumor volume for the treated group. This significant therapeutic effect was maintained
throughout the 42 days long study. Tumors harvested from the treatment group consisted largely of necrotic tissue,
indicating extensive death of tumor cells

Table 1.  ARRIVE description.
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